老年痴呆异常黑胆质病证结合模型的建立及异常黑胆质成熟剂的干预研究
|
摘要
目的：以维医体液病理学证候模型拟临床研究概念为指导,在前期疾病模型研究和临床研究的基础上,首次建立老年痴呆异常黑胆质病证结合大鼠模型,从行为学及病理、生化等多层面、多指标揭示异常黑胆质证的本质、揭示病证结合模型发展规律及其内在演化本质,并用异常黑胆质成熟剂对此模型进行干预,评价药物的作用和作用机理,从疾病内在本质构建符合维医药作用特点的药物评价技术及研究平台。方法：运用维吾尔医学异常黑胆质论,从产生异常黑胆质证的病因因素入手,应用干寒环境+慢性电刺激+干寒属性饲料,观察动物体表特征如舌象、毛皮、体重、饮食、活动、反应情况等验证维医体液证侯改变特点,建立异常黑胆质证大鼠模型基础上,再予以聚集态Aβ1-40双海马定向注射制备老年痴呆异常黑胆质病证结合大鼠模型。应用Morris水迷宫及跳台法等行为学试验观察病证结合大鼠模型的行为学改变;采用HE染色,Bielschowsky氏改良染色、刚果红染色等方法观察各组模型大鼠海马形态学的变化：采用电镜技术观察各组大鼠海马神经超微结构观察神经元、神经突触的变化；采用免疫组化法检测海马区Aβ1-40、COX-2、IκB-α、nNOS蛋白的表达；应用紫外分光光度法检测模型大鼠海马组织超氧化物歧化酶(SOD)活性、谷胱甘肽过氧化物酶(GSH-Px)活性、过氧化氢酶(CAT)活性、总抗氧化能力(T-AOC)、单胺氧化酶(MAO)活性、丙二醛(MDA)浓度；采用分光光度法检测各组大鼠胆碱乙酰转移酶(ChAT)、乙酰胆碱酯酶(AChE)活性,应用酶联免疫分析(ELISA)检测乙酰胆碱浓度；代谢组学技术检测各组模型代谢物的改变,在此模型的基础上以异常黑胆质成熟剂高、中、低剂量干预治疗后,应用上述方法检测异常黑胆质成熟剂对变化指标的影响。结果：①生物表征观察结果显示：异常黑胆质证模型组出现了舌质暗红、红紫色黯、欠津,毛色发黄黯淡无光泽,反应迟钝,烦躁争抢食水但体重明显下降,出现消瘦、腹部凹陷松软的表象等生物表征。而正常对照组大鼠发育正常。上述生物表征在造模第14天时明显于第7天。与正常对照组比较异常黑胆质证模型组大鼠每100g体重平均进食饮水量明显增加(P<0.01),而体重明显减轻(P<0.01),异常黑胆质证模型的生物表征发生了明显的改变；痴呆异常黑胆质病证结合模型生物表征的改变较单纯异常黑胆质证模型更加明显；病证结合组与异常黑胆质证组比较争食水减少,反应迟钝,舌质紫黯更明显且舌欠津；不仅掉毛增多,由于活动减少,较少清理毛发故毛中见木屑多,形体日渐消瘦,腹部内凹、弓背以病证结合组更为明显。统计数据也表明与正常对照组相比病证结合组体重减轻(P<0.01),饮食、水量反较异常黑胆质期减少,体重减轻明显,体型瘦弱。②Morris水迷宫定位航行实验中,病证结合组与单纯痴呆组学习记忆能力明显下降,病证结合组与单纯痴呆组相比,潜伏期明显延长；空间探索实验中,病证结合组与单纯痴呆组相比经过有效区域次数明显减少(P<0.01)；跳台测试结果显示：单纯痴呆组、异常黑胆质证组和痴呆异常黑胆质病证结合组学习记忆成绩明显降低,与正常对照组比较(P<0.01)；异常黑胆质证组开始训练时成绩与正常对照组差异不明显,但第3、4天与正常对照组寻找平台的时间差异明显,提示异常黑胆质证对模型的学习行为能力有影响。病证结合组从开始训练到实验结束游泳轨迹都杂乱无章,在每个时间点都与正常对照组有显著差异(P<0.01)。③HE染色结果显示：痴呆异常黑胆质病证结合模型组大鼠海马神经元细胞明显减少,与正常对照组、单纯痴呆组比较数目减少有显著统计学差异(P<0.01),提示神经元坏死数目减少比单纯痴呆组明显：⑤Bielschowsky氏改良染色：正常对照组结果显示阴性,未见明显神经纤维缠结及老年斑。痴呆异常黑胆质病证结合组神经元纤维增粗,排列紊乱,密集成团块状较单纯痴呆组多见,轴突呈编织状遍布细胞质并深入到细胞突起,在胞浆内有形成螺旋扭曲,形成神经纤维缠结。⑤刚果红染色：痴呆异常黑胆质病证结合组可见大量散在分布的橘红色沉积物,阳性染色呈现嗜红色或者砖红色样改变,提示老年斑形成。⑥透射电镜结果显示：痴呆异常黑胆质病证结合模型组核膜不清楚,线粒体结构紊乱,突触形态异常,结构模糊,前、后膜不清晰,数量明显减少,神经损伤最为严重。⑦免疫组织化学结果显示：Aβ1-40阳性细胞在病证结合模型组反应强度明显高于正常对照及单纯痴呆组,在海马区阳性细胞数与前两组比较,差异有显著性意义(P<0.01)。而nNOS的阳性表达明显减弱,COX-2、IκB-a在病证结合模型组的表达强度和阳性细胞数的增加与正常对照组比较(P<0.01)。⑧生化指标检测结果显示：与正常对照组比较,痴呆异常黑胆质病证结合组大鼠海马SOD、GSH-PX、CAT活性及总抗氧化能力均降低,MAO活性增强,氧化产物MDA含量增高(P<0.01)。异常黑胆质证组各项指标较正常对照组都有改变,CAT的减少与正常对照组比较差异有显著统计学意义(P<0.01)。痴呆异常黑胆质病证结合大鼠模型的总抗氧化能力与单纯痴呆组比较有明显差异(P<0.05)。痴呆异常黑胆质病证结合大鼠模型氧化损伤、脂质过氧化损伤、单胺类神经递质被氧化分解最为严重。⑨胆碱能神经指标检测结果显示：异常黑胆质证组大鼠模型的乙酰胆碱含量及胆碱乙酰转移酶活性的改变与正常对照组比较,差异有明显统计学意义(P<0.05),而痴呆异常黑胆质病证结合组与正常对照组比较乙酰胆碱含量、胆碱乙酰转移酶活性及乙酰胆碱酯酶活性均有显著差异(P<0.01),痴呆异常黑胆质病证结合组大鼠模型在中枢胆碱能的损伤最为明显。⑩异常黑胆质证导致模型发生了糖代谢紊乱与能量代谢障碍,代谢物的变化表明不同模型间的代谢产物具有差异性,痴呆异常黑胆质病证结合动物模型体内糖代谢紊乱和能量代谢障碍与单纯痴呆模型及异常黑胆质证模型比较代谢产物及代谢途径在病变过程中发生了演变,痴呆异常黑胆质病证结合动物模型的代谢变化更为复杂。0药物干预治疗结果显示：异常黑胆质成熟剂高剂量组在第二天的平均潜伏期成绩明显优于其他组,与模型组大鼠比较,异常黑胆质成熟剂高、中、低剂量组在第3、4天空间记忆显著提高,潜伏期明显缩短,与多奈哌齐组比较无统计学差异(P>0.05)；与正常对照组及多奈哌齐组比较,各剂量组经过有效区域次数均无明显差异(P>0.05)；与模型组比较跳台实验中个治疗组大鼠潜伏期缩短和错误次数降低(P<0.01),与多奈哌齐组也无明显差异(P>0.05)。HE染色异常黑胆质成熟剂中、低剂量组对组织病理学改变作用不明显,但高剂量干预组HE染色其锥体细胞层较完整,细胞排列较整齐,结构形态正常,染色正常,仅可见少量固缩状的坏死神经元,Bielschowsky氏改良染色正常组未见神经纤维缠结,刚果红染色可见少量散在老年斑,高剂量干预组形态学观察与多奈哌齐组接近,对损伤的神经具有相同的改善作用。电镜超微结构见高剂量的异常黑胆质成熟剂可增加神经突触的数量,改善突触前后膜的结构,保护线粒体的损伤,疗效优于多奈哌齐组；与模型组比较,有高剂量异常黑胆质成熟剂可明显抑制Aβ1-40、COX-2,1κB-α的表达,而促进nNOS表达(P<0.01)；抗氧化酶活性在异常黑胆质成熟剂干预治疗后均有不同程度的改善,其中异常黑胆质成熟剂高剂量显著提高抗氧化酶活性及总体抗氧化能力,减少模型大鼠海马区的脂质过氧化物MDA的含量,有效保护模型大鼠神经细胞的氧化损伤；异常黑胆质成熟剂明显减低MAO酶活性,明显抑制病证结合模型的AchE活性,增强ChAT活性,增加Ach的含量,和多奈哌齐组比较组间差异无统计学意义。代谢组学分析不同剂量的异常黑胆质成熟剂对与糖代谢相关代谢产物及与氨基酸合成代谢相关代谢产物有不同程度的调节作用,从而改善神经细胞的糖代谢紊乱和能量代谢障碍。结论：(1)首次在异常黑胆质证模型的基础上双海马Aβ1-40注射术建立痴呆异常黑胆质病证结合模型,此模型将“病”和“证”的因素集于一体,与单纯痴呆模型、异常黑胆质证模型比较,病证结合模型大鼠在体征和行为学方面的变化上不仅具有维医体液证候特点,而且具有AD学习记忆受损的西医疾病的特点；学习记忆受损程度,神经损伤从神经元的数目、神经纤维缠结的程度及老年斑的形成以及从加速这种病变的因子的表达最为明显；神经细胞氧化应激损伤、脂质过氧化损伤、单胺类神经递质被氧化分解最为严重,中枢胆碱能神经损伤最为突出,代谢产物差异性更复杂。发现AD与异常黑胆质证具有相对一致的生物学基础紊乱,异常黑胆质证所造成的病理改变对Aβ的神经毒性造成的神经损伤不仅有协同的作用,部分改变还发生了叠加,进一步加重了模型的生物学基础的改变,此模型能更好的成为维医体液论和老年痴呆的基础研究的动物模型,为今后异常黑胆质型痴呆的发病机制及防治研究奠定动物实验基础。(2)异常黑胆质成熟剂对痴呆异常黑胆质病证结合模型大鼠的学习记忆有显著改善作用；可改善受损神经元细胞的组织结构,减少神经细胞损伤,减轻神经纤维缠结的程度及老年斑的形成,抑制Aβ1-40、COX-2、IκB-α表达,增加nNOS表达水平,加速NO合成,减轻氧自由基对模型大鼠神经细胞的氧化损伤,能显著改善模型大鼠神经细胞氧化应激损伤,抑制海马AchE活性,增强ChAT活性,增加ACh的含量,对模型组大鼠的胆碱能系统的损伤有修复作用,不同剂量的异常黑胆质成熟剂对与糖代谢相关代谢产物及与氨基酸合成代谢相关代谢产物有不同程度的调节作用。异常黑胆质成熟剂可通过直接或间接地改善炎症反应、氧化应激、胆碱能系统的损伤,调节代谢障碍。异常黑胆质成熟疗法减轻Aβ神经毒性作用造成大脑海马神经元损伤而提高学习记忆能力、认知水平,改善“痴呆”症状。本实验也证明异常黑胆质成熟疗法具有多靶点、多途径、多层次、整体治疗的特点。
Objective:In this study, under the guidance of Hilit phathology theory of Uighur medicine, as well as on the basis of research on disease model and clinical research established Alzheimer disease rat model with Abnormal Savda Syndrome. From more perspectives of behavioral science, the pathological and biochemical indicators reveal the nature of the Abnormal Savda Syndrome, reveal the regulation of development and its inner nature of evolution,comprehensively and accurately revealed the nature of syndrome with diseases. I addition, we used the Abnormal Savda Munziq to treat Alzheimer disease with Abnormal Savda Syndrome rat model, and clarified the mechanism of Abnormal Savda Munziq on Alzheimer's disease. Method:We applied the Uighur medicine Savda syndrome theory, and proceeded with the etiological factors of Abnormal Savda such as dry-cold environment,(psychological)chronic electronic shock and dry-cold feed to establish Abnormal Savda Syndrome rat model to observe biological character such tongue, for, weight, diet, acitivity, response to validate the biological characteristics of Savda syndrome. Then the incubated Aβ1-40was injected into both hippocampus of each rat, enabling it to obtain the characteristics of both the western medicine of disease, and the characteristics of Savda syndrome. The behavioral abnormalities were investigated by Morris water maze test and step-down phases test. Rat brain sections were detected by HE staining, transmission electron microscopy and immunohistochemistry for Aβ1-40、COX-2、IκB-α、nNOS expression. RT-PCR for COX-2、IκB-α、nNOS expression of mRNA. Acetylcholine (ACh) levels, acetylcholineesterase (AChE) activity, Choline acetyltransferase (ChAT) activity, monoamine oxidase (MOA), oxidative stress markers (SOD, GSHPx, T-AOC, CAT and MDA) were assessed in the hippocampus. Metabonomics technology to detect changes in metabolites. After model stage, ASMq and donepezil were orally administered to AD rats for14days after7days Aβ1-40injected to hippocampus. Invesitigate the therapeutic potential mechanism of ASMq to ameliorate AD-like pathology in the brain of AD rats with Savda syndrome. Results:①The change of biological characterization of the Abnormal savda syndrome model:Abnormal savda syndrome rat model group appeared dark red tongue, red and purple, the hair color is yellow, dim and dull, lags in response, dull copetition for water and feeding, but the weight loss evidently, appeared weight was lossed, representation symptoms of abdominal deboss loosing While normal control group's rats can growth normally, the above symptoms were clear in model rats in fourteenth days than seventh days. The results show that the amount of eating and drinking consumption of the abnormal savda syndrome rat model group for each100g rat's weight increased significantly in compared with the normal control group (P<0.01), and the weight loss significantly (P<0.01). Thus it can be seen that, under the condition of three factors the biological characterization of Alzheimer's disease (AD) with Abnormal Savda Syndrome rat model, combination AD with Abnormal Savda Syndrome rat model, and its biological characterization of the change were obviously than the Abnormal Savda Syndrome. The response of combination disease with syndrome group's fighting was reduced than the abnormal savda group, dark purple tongue also more obviously than abnormal savda group. Not only hair loss were increased, rat activity were decreased, body weight were decreased, showed abdominal concave were much more obvious of combination disease with syndrome group. Statistics show that weight losing (P<0.01), food, water consumption were much more obvious when compared with the normal control group.②Spatial learning and memory ability:Morris water maze test results showed that decrease ability of learning and memory of the combination AD with Abnormal Savda Syndrome and AD model group's than another group. The potential latency of the combination AD with Abnormal Savda Syndrome rat model group was decreased much more obviously when compared with AD group, in the space exploration number of through the effective area was significantly reduced (P<0.01). The abnormal savda syndrome group began training the marks were not significantly different than the normal control group, but the third,4th days the searching platform time has differences between groups, indicated that that abnormal savda damaged learning behavior ability of model. The experiment track of combination AD with Abnormal Savda syndrome group were disorder from in the beginning to the end, also at each time point has significant difference (P<0.01).Results of the step-down test also show that learning and memory performance of simple AD group, the abnormal savda syndrome group and Alzheimer disease with Abnormal Savda Syndrome rat model were decreased significantly (P<0.01).③HE staining:Combination AD with Abnormal Savda Syndrome rat model group, the rat's hippocampal neurons number were significantly reduced than the normal control group and simple AD group, and it also has significant statistical diffeences (P<0.01), necrosis of neurons, decreased in number than the AD group.④Modified Bielschowsky's staining:results showed that in combination AD with Abnormal savda syndrome thickening neuronal fiber, arranged in disorder, densely integrated mass can be seen more than simply AD group rat, axons was woven throughout the cytoplasm and deep into the cell processes, have formed spirally twisted in the cytoplasm, and formed neurofibrillary tangle.⑤Congo red staining:results showed that staining in normal group and abnormal savda syndrome group showed negative, not seen obviously neurofibrillary tangles and senile plaques. Congo red staining in combination AD with Abnormal savda syndrome showed a large number of scattered red sediments, positive staining showed eosinophilic red or red brick like changing, suggesting the formation of senile plaques.⑥Transmission electron microscope:Ultrastructure observation showed that neurons distribution and nuclear membrane unclear in combined AD with Abnormal savda syndrome group, we found that disordering structure of mitochondrial, synaptic's abnormal morphology, fuzzy structure, before and after the film is not clear, the number decreased evidently, nerve injury is the most severe.⑦Immunohistochemical:Aβ1-40positive cells in the combination AD with Abnormal savda syndrome group in the reaction intensity was significantly higher than that of normal control and the AD group, positive cells number in the hippocampus compared with the two other groups, they have significance diffirences in their cells number (P<0.01). While the expression of nNOS was significantly decreased, COX-2, IκB-a expression were increased in the combination of AD with Abnormal savda syndrome group compared with normal control group (P<0.01);⑧Biochemistry biomarker:Antioxidant biomarkers were changed in rats combination AD with Abnormal savda syndrome to compare with the normal contract group. SOD, GSH-Px and CAT activity were decreased, MAO was increased compared with normal control group (P<0.01). There was had significant difference in total antioxidant capacity of combination AD with Abnormal Savda Syndrome rat model's comparered with simple AD group (P<0.05), indicated that there were severe oxidative damage, lipid peroxidation damage, oxidative decomposition of monoamine neurotransmitters in the combination AD with abnormal savda syndrome's.⑨Study on the damage of cholinergic neurons:there was acetylcholinesterase (AChE) activity in brain increased obviously in the combination AD with Abnormal Savda Syndrome model's, but choline acetyltransferase activity significantly decreased, as well as acetylcholine content was decreased when compare with the normal control group (P<0.01). Acetylcholine content was decreased, and acetylcholineesterase (AChE) activity was increased in the brain of Abnormal savda syndrome compared with the normal control group, there was significant difference (P<0.05), while content of acetylcholine, acetylcholineesterase (AchE) activity, choline acetyltransferase activity of the combination of disease with syndrome group have significant difference with the normal control group (P<0.01). damage of central cholinergic of combination AD with Abnormal Savda Syndrome model's is the most obvious.⑩Abnormal black bile leads to the sugar metabolic disorders and energy metabolism dysfunction, metabolite changes showed that the metabolites are different between different models, the metabolic changes of combining AD with syndrom groups are more complex.11Intervention of Abnormal Savda Munziq(ASMq):Results show that Abnormal Savda munziq high dose group significantly improve the average latency performance in the second compared with model group, in the third,4days all the ASMq three dosage groups significantly improved spatial memory and escape latency period, there was no significantly statistical difference compare with donepezil group(p>0.05). There were no significant difference in the navigation test, number of pass the effective area of all treatment group compare with normal control group and donepezil group(p>0.05), there are no significant differences between donepezil group and step-down test(p>0.05). Histological results showed that HE staining, there are not evident curative effect of low dosage treatment with ASMq, But the high dose group, HE staining of the pyramidal cell layer of relatively complete, cells were arranged in order, the structure of morphology is normal, normally staining, only a small amount of pyknotic neuron necrosis can be seen. Modified Bielschowsky's staining results showed no neurofibrillary tangles, found a altered in a small amount of senile plaques in Congo red staining, in the high dose treatment group morphological observation is similar to donepezil group, showed a neuroprotective effect. This study was limited to the CA1hippocampal region. In normal group brains, no observe indications of neurodegeneration were observed. Most of the neurons with normal morphology (large, round, or oval nuclei, synaptic contacts on the soma, well-developed rough endoplasmic reticulum, and Golgi complex) had smooth cytoplasmic membranes marked only infrequently by small irregular in foldings. Rough endoplasmic reticulum was identified by the presence of ribosomes on its surface, mitochondria appeared as electron-dense oval structures with regular cristae inside and nuclei displayed smooth membranes. Different from many cells with apparently normal morphology, in model rat brains, some neurons and their organelles appeared to have undergone transformations, such as dilated rough endoplasmic reticulum and dilated mitochondria with fewer cristae inside, or even both cytoplasmic and nuclear membranes showing deep infoldings. Few of the damaged structures displayed specific chromatin heterocondensation and marginalisation, typical of apoptotic death. In ASMq treated brains, many neurons appeared to be with similar morphology to normal ones. Except for occasionally deformed mitochondrions recognized by remnants of cristae, rare autophagosomes, and dilated Golgi complex and reticulum, no additional organelles could be identified abnormal. ASMq can increase the number of synapses, can improve the structure of synaptic's before and after membranes, reduce the damage of mitochondria, curative effect is better than that of donepezil group. Immunohistochemistry research results show that high doses of ASMq could significantly inhibit the number of Aβ1-40positive cells, and increase the expression of nNOS. As to the number of COX-2cells, there is obvious inhibitory effect between high dose group and model group. High dose ASMq reduced the IκB-α immunoreactive expression in the hippocampus, the reaction intensity decreased, the number of positive cells decreased, reaching the level of the normal control grop. The expression of mRNA; After ASMq intervention on treatment, Activities of antioxidant enzymes have improved in the varying degrees, Statistical results showed high dose of ASMq can significantly improve the oxidative stress statues of rats, increase the activities of antioxidant enzymes and total antioxidant capacity, can significantly reduce the content of lipid peroxide MDA in model rat's hippocampus, evidently decrese the enzyme activity of MAO, High doses of ASMq could significantly inhibit the combination disease and syndrome model's AchE activity, Increased ChAT activity, increased Ach contents, and there is no statistical significance between donepezil group and high dosage group. Metabonomics analysis of different doses of ASMq on amino acid and sugar metabolism have different degree of regulation, can improve the sugar metabolic disorders and energy metabolism of nerve cells disorder.Conclusion:(1) We firstly establish combination Alzheimer disease rat model with Abnormal Savda Syndrome according to the basis of abnormal savda syndrome model and bilateral hippocampal injection of Aβ1-40, the model will be combine "disease" and "syndrome" in one time, the learning and memory impairment obviously of the combination AD with Abnormal savda syndrome model than the simple model of AD induced bilateral hippocampal injection of Aβ1-40and Abnormal savda syndrome model, Histopathological changes such as neurone damage, neurofibrillary tangles and senile plaques were was significantly combination AD with Abnormal savda syndrome model than the Aβ1-40induced AD model. Oxidative damage, lipid peroxidation, monoamine neurotransmitters oxidative decomposition are the most serious in the AD with Abnormal savda syndrome model brain. The central cholinergic nervous system damaging was much more obvious, This is would be not only animal model for disease differentiation but also syndrome differentiation on the basis of the Uighur humor theory and AD, should accord with clinical practice of AD, The rat model of combined disease with syndrome can comprehensively reflect the character of AD aspects from both western medicine and Uighur Medicine as well as from etiology and pathology. It will become the ideal animal model study AD, also a ideal model research Uighur medicine effect and its treatment target.(2) ASMq significantly improved learning and memory of combined AD with savda syndrome in rats. It can improve the organizational structure of the damaged neurons cells, reduce the cell damaged, reduce the formation of neurofibrillary tangles and senile plaque, inhibit the positive expression Aβ1-40, COX-2, IκB-α, increased nNOS levels, accelerate the synthesis of NO, can significantly improve the oxidative stress in rats, reducing the oxygen free radical on nerve cells in a rat model. Inhibition of AchE activity, increased ChAT activity, increasing the content of Ach, and agitating M receptor activation of cholinergic neurons. Different doses of ASMq on amino acid and sugar metabolism have different degree of regulation.It can also improve the inflammation by direct or indirect way, oxidative stress, cholinergic system damaged, increased Aβ clearance, relieve Aβ metabolic disturbance, relieve damaging of hippocampal neurons caused by Aβ neurotoxicity, while improve the learning ability, memory, cognitive level, improve AD symptoms.
Objective:In this study, under the guidance of Hilit phathology theory of Uighur medicine, as well as on the basis of research on disease model and clinical research established Alzheimer disease rat model with Abnormal Savda Syndrome. From more perspectives of behavioral science, the pathological and biochemical indicators reveal the nature of the Abnormal Savda Syndrome, reveal the regulation of development and its inner nature of evolution,comprehensively and accurately revealed the nature of syndrome with diseases. I addition, we used the Abnormal Savda Munziq to treat Alzheimer disease with Abnormal Savda Syndrome rat model, and clarified the mechanism of Abnormal Savda Munziq on Alzheimer's disease. Method:We applied the Uighur medicine Savda syndrome theory, and proceeded with the etiological factors of Abnormal Savda such as dry-cold environment,(psychological)chronic electronic shock and dry-cold feed to establish Abnormal Savda Syndrome rat model to observe biological character such tongue, for, weight, diet, acitivity, response to validate the biological characteristics of Savda syndrome. Then the incubated Aβ1-40was injected into both hippocampus of each rat, enabling it to obtain the characteristics of both the western medicine of disease, and the characteristics of Savda syndrome. The behavioral abnormalities were investigated by Morris water maze test and step-down phases test. Rat brain sections were detected by HE staining, transmission electron microscopy and immunohistochemistry for Aβ1-40、COX-2、IκB-α、nNOS expression. RT-PCR for COX-2、IκB-α、nNOS expression of mRNA. Acetylcholine (ACh) levels, acetylcholineesterase (AChE) activity, Choline acetyltransferase (ChAT) activity, monoamine oxidase (MOA), oxidative stress markers (SOD, GSHPx, T-AOC, CAT and MDA) were assessed in the hippocampus. Metabonomics technology to detect changes in metabolites. After model stage, ASMq and donepezil were orally administered to AD rats for14days after7days Aβ1-40injected to hippocampus. Invesitigate the therapeutic potential mechanism of ASMq to ameliorate AD-like pathology in the brain of AD rats with Savda syndrome. Results:①The change of biological characterization of the Abnormal savda syndrome model:Abnormal savda syndrome rat model group appeared dark red tongue, red and purple, the hair color is yellow, dim and dull, lags in response, dull copetition for water and feeding, but the weight loss evidently, appeared weight was lossed, representation symptoms of abdominal deboss loosing While normal control group's rats can growth normally, the above symptoms were clear in model rats in fourteenth days than seventh days. The results show that the amount of eating and drinking consumption of the abnormal savda syndrome rat model group for each100g rat's weight increased significantly in compared with the normal control group (P<0.01), and the weight loss significantly (P<0.01). Thus it can be seen that, under the condition of three factors the biological characterization of Alzheimer's disease (AD) with Abnormal Savda Syndrome rat model, combination AD with Abnormal Savda Syndrome rat model, and its biological characterization of the change were obviously than the Abnormal Savda Syndrome. The response of combination disease with syndrome group's fighting was reduced than the abnormal savda group, dark purple tongue also more obviously than abnormal savda group. Not only hair loss were increased, rat activity were decreased, body weight were decreased, showed abdominal concave were much more obvious of combination disease with syndrome group. Statistics show that weight losing (P<0.01), food, water consumption were much more obvious when compared with the normal control group.②Spatial learning and memory ability:Morris water maze test results showed that decrease ability of learning and memory of the combination AD with Abnormal Savda Syndrome and AD model group's than another group. The potential latency of the combination AD with Abnormal Savda Syndrome rat model group was decreased much more obviously when compared with AD group, in the space exploration number of through the effective area was significantly reduced (P<0.01). The abnormal savda syndrome group began training the marks were not significantly different than the normal control group, but the third,4th days the searching platform time has differences between groups, indicated that that abnormal savda damaged learning behavior ability of model. The experiment track of combination AD with Abnormal Savda syndrome group were disorder from in the beginning to the end, also at each time point has significant difference (P<0.01).Results of the step-down test also show that learning and memory performance of simple AD group, the abnormal savda syndrome group and Alzheimer disease with Abnormal Savda Syndrome rat model were decreased significantly (P<0.01).③HE staining:Combination AD with Abnormal Savda Syndrome rat model group, the rat's hippocampal neurons number were significantly reduced than the normal control group and simple AD group, and it also has significant statistical diffeences (P<0.01), necrosis of neurons, decreased in number than the AD group.④Modified Bielschowsky's staining:results showed that in combination AD with Abnormal savda syndrome thickening neuronal fiber, arranged in disorder, densely integrated mass can be seen more than simply AD group rat, axons was woven throughout the cytoplasm and deep into the cell processes, have formed spirally twisted in the cytoplasm, and formed neurofibrillary tangle.⑤Congo red staining:results showed that staining in normal group and abnormal savda syndrome group showed negative, not seen obviously neurofibrillary tangles and senile plaques. Congo red staining in combination AD with Abnormal savda syndrome showed a large number of scattered red sediments, positive staining showed eosinophilic red or red brick like changing, suggesting the formation of senile plaques.⑥Transmission electron microscope:Ultrastructure observation showed that neurons distribution and nuclear membrane unclear in combined AD with Abnormal savda syndrome group, we found that disordering structure of mitochondrial, synaptic's abnormal morphology, fuzzy structure, before and after the film is not clear, the number decreased evidently, nerve injury is the most severe.⑦Immunohistochemical:Aβ1-40positive cells in the combination AD with Abnormal savda syndrome group in the reaction intensity was significantly higher than that of normal control and the AD group, positive cells number in the hippocampus compared with the two other groups, they have significance diffirences in their cells number (P<0.01). While the expression of nNOS was significantly decreased, COX-2, IκB-a expression were increased in the combination of AD with Abnormal savda syndrome group compared with normal control group (P<0.01);⑧Biochemistry biomarker:Antioxidant biomarkers were changed in rats combination AD with Abnormal savda syndrome to compare with the normal contract group. SOD, GSH-Px and CAT activity were decreased, MAO was increased compared with normal control group (P<0.01). There was had significant difference in total antioxidant capacity of combination AD with Abnormal Savda Syndrome rat model's comparered with simple AD group (P<0.05), indicated that there were severe oxidative damage, lipid peroxidation damage, oxidative decomposition of monoamine neurotransmitters in the combination AD with abnormal savda syndrome's.⑨Study on the damage of cholinergic neurons:there was acetylcholinesterase (AChE) activity in brain increased obviously in the combination AD with Abnormal Savda Syndrome model's, but choline acetyltransferase activity significantly decreased, as well as acetylcholine content was decreased when compare with the normal control group (P<0.01). Acetylcholine content was decreased, and acetylcholineesterase (AChE) activity was increased in the brain of Abnormal savda syndrome compared with the normal control group, there was significant difference (P<0.05), while content of acetylcholine, acetylcholineesterase (AchE) activity, choline acetyltransferase activity of the combination of disease with syndrome group have significant difference with the normal control group (P<0.01). damage of central cholinergic of combination AD with Abnormal Savda Syndrome model's is the most obvious.⑩Abnormal black bile leads to the sugar metabolic disorders and energy metabolism dysfunction, metabolite changes showed that the metabolites are different between different models, the metabolic changes of combining AD with syndrom groups are more complex.11Intervention of Abnormal Savda Munziq(ASMq):Results show that Abnormal Savda munziq high dose group significantly improve the average latency performance in the second compared with model group, in the third,4days all the ASMq three dosage groups significantly improved spatial memory and escape latency period, there was no significantly statistical difference compare with donepezil group(p>0.05). There were no significant difference in the navigation test, number of pass the effective area of all treatment group compare with normal control group and donepezil group(p>0.05), there are no significant differences between donepezil group and step-down test(p>0.05). Histological results showed that HE staining, there are not evident curative effect of low dosage treatment with ASMq, But the high dose group, HE staining of the pyramidal cell layer of relatively complete, cells were arranged in order, the structure of morphology is normal, normally staining, only a small amount of pyknotic neuron necrosis can be seen. Modified Bielschowsky's staining results showed no neurofibrillary tangles, found a altered in a small amount of senile plaques in Congo red staining, in the high dose treatment group morphological observation is similar to donepezil group, showed a neuroprotective effect. This study was limited to the CA1hippocampal region. In normal group brains, no observe indications of neurodegeneration were observed. Most of the neurons with normal morphology (large, round, or oval nuclei, synaptic contacts on the soma, well-developed rough endoplasmic reticulum, and Golgi complex) had smooth cytoplasmic membranes marked only infrequently by small irregular in foldings. Rough endoplasmic reticulum was identified by the presence of ribosomes on its surface, mitochondria appeared as electron-dense oval structures with regular cristae inside and nuclei displayed smooth membranes. Different from many cells with apparently normal morphology, in model rat brains, some neurons and their organelles appeared to have undergone transformations, such as dilated rough endoplasmic reticulum and dilated mitochondria with fewer cristae inside, or even both cytoplasmic and nuclear membranes showing deep infoldings. Few of the damaged structures displayed specific chromatin heterocondensation and marginalisation, typical of apoptotic death. In ASMq treated brains, many neurons appeared to be with similar morphology to normal ones. Except for occasionally deformed mitochondrions recognized by remnants of cristae, rare autophagosomes, and dilated Golgi complex and reticulum, no additional organelles could be identified abnormal. ASMq can increase the number of synapses, can improve the structure of synaptic's before and after membranes, reduce the damage of mitochondria, curative effect is better than that of donepezil group. Immunohistochemistry research results show that high doses of ASMq could significantly inhibit the number of Aβ1-40positive cells, and increase the expression of nNOS. As to the number of COX-2cells, there is obvious inhibitory effect between high dose group and model group. High dose ASMq reduced the IκB-α immunoreactive expression in the hippocampus, the reaction intensity decreased, the number of positive cells decreased, reaching the level of the normal control grop. The expression of mRNA; After ASMq intervention on treatment, Activities of antioxidant enzymes have improved in the varying degrees, Statistical results showed high dose of ASMq can significantly improve the oxidative stress statues of rats, increase the activities of antioxidant enzymes and total antioxidant capacity, can significantly reduce the content of lipid peroxide MDA in model rat's hippocampus, evidently decrese the enzyme activity of MAO, High doses of ASMq could significantly inhibit the combination disease and syndrome model's AchE activity, Increased ChAT activity, increased Ach contents, and there is no statistical significance between donepezil group and high dosage group. Metabonomics analysis of different doses of ASMq on amino acid and sugar metabolism have different degree of regulation, can improve the sugar metabolic disorders and energy metabolism of nerve cells disorder.Conclusion:(1) We firstly establish combination Alzheimer disease rat model with Abnormal Savda Syndrome according to the basis of abnormal savda syndrome model and bilateral hippocampal injection of Aβ1-40, the model will be combine "disease" and "syndrome" in one time, the learning and memory impairment obviously of the combination AD with Abnormal savda syndrome model than the simple model of AD induced bilateral hippocampal injection of Aβ1-40and Abnormal savda syndrome model, Histopathological changes such as neurone damage, neurofibrillary tangles and senile plaques were was significantly combination AD with Abnormal savda syndrome model than the Aβ1-40induced AD model. Oxidative damage, lipid peroxidation, monoamine neurotransmitters oxidative decomposition are the most serious in the AD with Abnormal savda syndrome model brain. The central cholinergic nervous system damaging was much more obvious, This is would be not only animal model for disease differentiation but also syndrome differentiation on the basis of the Uighur humor theory and AD, should accord with clinical practice of AD, The rat model of combined disease with syndrome can comprehensively reflect the character of AD aspects from both western medicine and Uighur Medicine as well as from etiology and pathology. It will become the ideal animal model study AD, also a ideal model research Uighur medicine effect and its treatment target.(2) ASMq significantly improved learning and memory of combined AD with savda syndrome in rats. It can improve the organizational structure of the damaged neurons cells, reduce the cell damaged, reduce the formation of neurofibrillary tangles and senile plaque, inhibit the positive expression Aβ1-40, COX-2, IκB-α, increased nNOS levels, accelerate the synthesis of NO, can significantly improve the oxidative stress in rats, reducing the oxygen free radical on nerve cells in a rat model. Inhibition of AchE activity, increased ChAT activity, increasing the content of Ach, and agitating M receptor activation of cholinergic neurons. Different doses of ASMq on amino acid and sugar metabolism have different degree of regulation.It can also improve the inflammation by direct or indirect way, oxidative stress, cholinergic system damaged, increased Aβ clearance, relieve Aβ metabolic disturbance, relieve damaging of hippocampal neurons caused by Aβ neurotoxicity, while improve the learning ability, memory, cognitive level, improve AD symptoms.
引文
[1]苏怡汀,李乐华.阿尔茨海默病的神经生物学发病机制及相关治疗研究进展[J].医学临床研究,2011,(5)：947-951.
[2]吴思缈,周黎明.阿尔茨海默病的发病机制及药物治疗的进展[J].四川生理科学杂志,2009,31(1)：36-39.
[3]Ferfi Cp, prince M, Bmyne C, et al. Global prevalence of dementia:a Delphi consensus study[J]. Lancet,2005,366:2112-2117.
[4]Alzheimer Disease Iniernational. alzCO. uk/researeh/statistics. html accessed on 2007-5-16.
[5]Alzheimer's Association.2009Alzheimer disease facts and figures[J] Alzheimers Dement,2009,5(3):234-270.
[6]Gorelick PB. Preventable Dementia[J]. New York:Oxford University Press,2003, 308-320
[7]Sujuan Gao, Hugh C, Hendrie, et al. The Relationships Between Age, Sex, and theIncidence of Dementia and Alzheimer Disease:A Meta-analysis[J]. Arch GenPsychiatry.1998;55:809-815.
[8]Sterling C, Andrew J, Leslie C, et al. The Relationship between fMRI Activation andCerebral Atrophy:Comparison of Normal Aging and Alzheimer Disease[J].2000, 11(3):179-187.
[9]Frisoni GB, Fratiglioni L, Fastbom J, et al. Mild cognitive impair-ment in thepopulation and physical health:data on 1435 individuals aged 75 to 95[J]. Gerontol A Biol Sci Med Sci,2000,55:M322-328.
[10]Tschanz JT, Corcoran C, Skoog I, et al. Dementia:the leading predictor of death in a defined elderly population:The Cache County Study[J]. Neurology,2004,62:1156-1162.
[11]Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synihetic amyloid betapeptide:isoform-speeific effects and imPlieations for late6onset Alzheimer disease. Proe Natl Aead SciUSA,1993,90(17):8098-8102.
[12]Sub GH, SharaA. A Review of the epidemiological transition in dementia:cross national comparisons of the indices related to Alzheimer, disease and vaseular dementia[J]. Acta psychiatry scand,2001,104(2):4-11.
[13]Anthony H, Vagnucci JR, William W Li. Alzheimer's disease and angiogenesis[J]. Lancet,2003,361:605-608.
[14]Forette F, Seux ML, Staessen JA, et al. The prevention of dementia withantihypertensive treatment:new evidence from the Systolic Hypertension inEurope(Syst-Eur)Study[J]. Arch Intern Med,2002,162:2046-2052.
[15]Tian J. Dementia in Asian Context. In:The Cambrige Handbook of Age and Ageing, eds. Malcolm Johnson. Cambridge University Press,2005,261-274.
[16]MichaelisML. Drugs targeting Alzheimers disease:some things old and some things new[J]. JPharmacolExpTher,2003,304(3):897-904.
[17]陈美婉,罗焕敏,肖飞等.秋水仙素诱导的神经元突起溃变对Ap分泌的影响[J].中国药理学通报,2008,12：51-56.
[18]Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease:progressand Problems on the road to the ropeuties[J]. Science,2002,297(5580):353-356.
[19]Mayeux, R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci,2003, 26:81-104.
[20]洪玉,周晓辉,马龙.新疆维汉两民族阿尔茨海默病A2M基因多态性分析[J].中国神经精神疾病杂志,2008,(06)334-337.
[21]Pappolla MA, Sos M, Omar RA, et al. Melaton in prevents death of neuro-blastoma cellsexposed to the Alzheimer amyloid peptide[J]. Neurosci,1997,17:1683-1690.
[22]Drouet B, Fifre A, Pincon RM, et al. ApoE protects cortical neurons against neurotoxicity induced by the nonfibrillar C-terminal domain of the amyloid-beta peptide[J]. Neurochem,2001,76(1):117-127.
[23]Haass C. Amyloidβ-Peptide is Produced by cultured cells during normal metabolism[J]. Nature,1992,359:322-325.
[24]hojiM. Production of the Alzheimer amyloid P-Protein by normal Proteolytic Processing[J]. Seienee,1992,258:126-129.
[25]Silkoe DJ. Alzheimersdisease:genesProtein, and therapy[J]. PhysiloRv,2001, 81(2):741-766.
[26]RogerN, Rosenberg MD. Translational research on the way to effective therapy for Alzheimer disease[J]. Aich Gen Psychiatry,2005,62(11):1186-1192.
[27]Mayeux, R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci,2003, 26:81-104.
[28]张惠淑,林群,杨东辉.阿尔茨海默症中Ap毒性机制研究进展[J].中国当代医.药,2009,09：29-30.
[29]张忠立,左月明.黑水缬草对老年痴呆模型大鼠脑内iNOS、COX-2和IκB-α表达的影响[J].中药材,2010,33(4：)：581-583.
[30]Itoh A, Nitta A, Nadai M, et al. Dysfunetion of cholinergic and dopainergic neuronal systems in beta-amyloid protein-infused rats[J]. Neurochem,1996, 66(3):1113-1117.
[31]Muir JL. Acetylcholine aging and Alzheimer's disease[J]. Pharmacol Biochem Behav,1997,56:687-696
[32]Auld DS, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic neuromdulators:A missing link Trends[J] Neurosci,1998,21:43-49.
[33]W illiams TI, Lynn BC, MarkesberyWR, et al. Increased lev-els of 4-hydroxynonenal and acrolein, neurotoxic markers oflipid peroxidation, in the brain in mild cognitive impairmentand early Alzheimer's disease. Neurobiol Aging, 2006,27(8):1094-1099
[34]Velenzuela M J, Sachdev P. Magnetic resonance spectroscopy in AD [J]. Neurology,2001,56(5):592-598.
[35]Garcias J M, Gavrila D, Antunez C,et al. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey[J]. Dement Geriatr Cogn Disord,2008, 26 (1):15-25.
[36]. Chna SL. Furukawa K, Mastton MP Presenilins and APP in neuritic and synaptic plasticity:implications from the pathogenesis of Alzheimer's disease[J]. Neuromolecular Med,2002,2:167-196
[37]宋琳,谢宁.地黄饮子改善痴呆大鼠学习记忆及其防治AD作用机理的实验研究[D],黑龙江：黑龙江中医药大学博士学位论文,2005,5.
[38]郭蕾,王永炎,张志斌.关于证候概念的诠释[J].北京中医药大学学报,2003,26(2)：5-8.
[39]赵慧辉,王伟.病证结合证候模型研究基本思路[J].中华中医药杂志2006；21(12)：762-764.
[40]热娜古丽,沙吉达,哈木拉提等.复杂性疾病异常黑胆质证及其血栓前状态的研究[J].中国中医基础医学杂志,2008,14(8)：614-615.
[41]阿不都热依木,阿衣木姑,哈木拉提.吾甫尔等.维医异常体液型冠心病与ACE、eNOS、FVII及ICAM-1基因多态性关系的研究[J].科技导报,2009,27(5)：19-27.
[42]哈木拉提.吾甫尔,阿不都热依木.玉苏甫,吐尔逊.吾甫尔.维医异常体液分型与年龄、性别关系的探讨[J].中国民族民间医药杂志,2003,61：84-86.
[43]哈木拉提.吾甫尔：维吾尔医气质、体液论及其现代研究[M].新疆：新疆科学技术 出版社,2003：34-38
[44]阿依努尔.买提斯迪克,胡汉华,哈木拉提.吾甫尔等.异常黑胆质载体动物模型支配器官组织细胞超微结构观察[J].新疆医科大学学报.2006,29：919-920.
[45]阿依努尔.买提斯迪克,尼加提.热合曼,哈木拉提.吾甫尔.异常黑胆质载体动物模型下丘脑—垂体—肾上腺轴组织形态学观察[J].新疆医科大学学报,2006,29：914-916.
[46]阿吉.阿布里米提,玉素甫,主编.维吾尔医学基础理论[M].乌鲁木齐：新疆人民卫生出版社,1988：114-144.
[47]木拉提.克扎衣别克,刘波.异常黑胆质成熟剂化学成分初步研究[J].时珍国医国药,2010,21(12)：3139-3141.
[48]努尔买买提,哈木拉提,阿迪力等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴的调节作用研究[J],时珍国医国药,2007,18(11)：2601-2603
[49]阿不都热依木,哈木拉提,斯拉甫等.异常黑胆质清除剂对线粒体氧化损伤的保护作用[J].中国中医基础医学杂志,2002,8(7)：38-40.
[50]阿地里江.阿不力米提,胡汉华,艾来提.米吉提等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴细胞超微结构的影响[J].国际病理科学与临床杂志,2007,27(3)：185-191.
[51]艾来提·米吉提,阿地里江·阿不力米提.维医异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴形态学的影响[J].国际病理科学与临床杂志,2008,28(1)：6-9.
[52]哈木拉提,阿不都热依木.维吾尔医成熟剂和清除剂抗活性氧的作用研究[J].中国民族医药杂志,2000,7(6)3：30-32.
[53]阿布都艾尼,阿不都热依木,哈木拉提等.异常黑胆质成熟剂和清除剂对OH·引发的DNA损伤的保护作用[J].中药药理与临床,2000,16(3)：34-36.
[54]阿布都艾尼,阿不都热依木.异常黑胆质成熟剂和清除剂对OH·引发的DNA损伤的保护作用[J]中药药理与临床2000；16(3)33-35.
[55]阿不都热依木.维医异常黑胆质成熟剂对HepG2细胞生长和凋亡及相关基因调控的研究[D].乌鲁木齐：新疆医科大学博士学位论文,2005.
[56]哈木拉提·吾甫尔,李林.异常黑胆质成熟剂与清除剂对氧化损伤的淋巴细胞p53蛋白表达的影响[J].新疆医科大学学报,2005,28(4)287-289.
[57]艾斯卡尔.依米提,哈木拉提.吾甫尔.维吾尔医成熟及清除剂诱导T淋巴瘤细胞凋亡的研究[J].中药药理与临床,2000；16(2)；33-34.
[58]阿不都热依木.玉苏甫.维医异常黑胆质成熟剂对HepG2细胞生长和凋亡及相 关基因调控的研究[D].乌鲁木齐：新疆医科大学,2005：121.
[59]阿不都热依木.玉苏甫,哈木拉提.吾甫尔等.异常黑胆质成熟剂黄酮类化合物诱导HepG2细胞凋亡机制的研究[J].中国中药杂志,2007,32(11)：1068
[60]Nurmuhammat Amat, Halmurat Upur, Adiljan Ablimit. Immunomodulatory effects of Abnormal SavdaMunsiq, a traditional Uighur medicine, on the combined stress mice[J], Journal of Ethnopharmacology,2009,122(1):42-47.
[61]梁妍琦,黄霄天,唐希灿.阿尔采末病发病机制及治疗药物研究进展[J].中国新药与临床杂志,2007,20(4)：641-648.
[62]张均田,石成璋,梅保幸等.“水迷宫”自动控制仪的研制及在神经药理研究中的应用[J].药物分析杂志,1991,11：23-26.
[63]阿依努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提‘艾买提等.异常黑胆质证载体动物模型的建立及其自然恢复反证[J].新疆医科大学学报,2006,29(10)：910-914.
[64]阿地力江,胡汉华,哈木拉提等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴细胞超微结构的影响[J].国际病理科学与临床杂志,2007,27(3)：185-191.
[65]依沙克江.穆罕穆德,主编.中国医学百科全书维吾尔医学分卷[M].第一册.乌鲁木齐：新疆人民卫生出版社.1985.
[66]Caroline. Beaufour, Nicolass Ballon. Efeects of chronic antidepressants in an Operant Confilic Procedure of Anxiety in the rat[J]. Pharmacology Biochemistry and Bahavior,1999,4(61):591-599
[67]Joao Palermo-Neto. Efeects of physical and psychological stressor on behavior and macrophage activity, and Ehrlich tumor growth[J]. Brain, Behavior and Immunity, 2003,(17)1:43-54.
[68]J. Kellet, extension deficit and fear reinstatement after electrical stimulation of theamygdale:implication for kindling-associated fear and anxiety[J]. neuroscience, 2004,127(2)277-287.
[69]哈木拉提·吾甫尔等.维吾尔医学气质、体液论及其现代研究[M].新疆科技术出版社,2003,7：75-77.
[70]陈小野.中医征候证候模型的制备方法概论[J].上海实验动物科学,1999,19(3)：191-193.
[71]刘晓伟,张红梅等.中医奴恐伤气证候模型制作及行为评估[J].2006,15(1)：10-11.
[72]Daniele Console, Julia Fedotova stressor affect the response of male and female rats to clomipramine in a model of behavioral despair[J]. European Journal of Pharma-cology,2005,520(1-3):100-107.
[73]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220.
[74]Jason Shumake, Douglas Barretr and F. Gonzalez-Lima Behavioral characteristics of rats predisposed to learned helplessness:Reduced reward sensitivity, increased novelty seeking, and persistent fear memories[J]. Behavioral Brain Research. 2005;165(2):222-230.
[75]George Paxinos, Charles Watson. The Rat Brain in Stereotaxic Coordinates[J]. Academic Press,1986:2.
[76]Morris RGM spatial localization does not require the presence of local cues[J] 1981 doi:10.1016/0023-9690(81)90020-5
[77]方福德.现代医学实验技巧全书.第一版.北京：北京医科大学和中国协和医科大学联合出版社[M],1995：420-425.
[78]张均田,张庆柱.神经药理研究技术与方法[M].北京：人民卫生出版社,2005,297-299.
[79]努尔买买提·艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究.乌鲁木齐：新疆医科大学博士论文.2007.1-3.
[80]雅森·米吉提,库热西·玉努斯,吐尔洪·吐送.维吾尔医学体液辩证分型及其相关疾病[J].新疆医科大学学报,2010.06：24-25.
[81]江维,哈木拉提·吾甫尔,吐尔洪·吐送等.维医异常黑胆质体液质高血压人群和正常黑胆质体液质健康人群肠道菌群多样性分析[J].中国病原生物学杂志,2012,02：58-62.
[82]阿地里江·阿布力米提.不同致病因素与异常黑胆质证候模型建立及其NEI网络和代谢组学的研究[D].新疆：新疆医科大学,2010：100-101.
[83]哈木拉提·吾甫尔.气质体液论及其现代研究[M].乌鲁木齐：新疆科技卫生出版社,2003.44-52.
[84]哈木拉提.维尔医学气质、体液论及其现代研究[M].乌鲁木齐：新疆科学技术出版社,2003,7：93-98.
[85]易沙克江.马合穆德,主编.中国医学百科全书维吾尔医学分卷,第六册[M].乌鲁木齐：新疆科技卫生出版社,1995,第一版.
[86]阿吉.阿布里米提.玉素甫主编.维吾尔医学基础理论[M]：乌鲁木齐：卫生厅人民卫生出版社,1988.
[87]伊沙克江·马合穆德,主编.中国医学百科全书维吾尔医学分册[M].第一册.乌鲁木齐：新疆人民卫生出版社.1988.第一版.
[88]阿地里江·阿布力米提不同致病因素与异常黑胆质证候模型建立及其NEI网络和代谢组学的研究[D].新疆：新疆医科大学博士研究生论文,2010.
[89]哈木拉提.吾甫尔.维吾尔医气质、体液论及其现代研究[M].新疆科学技术出版社.2003；34-38.
[90]Morris RG, Garrud P, Rawlins, JN, et al. Place navigation impaired in rats with hippocampal lesions. Nature,1982,297(5868):681-683.
[91]Fischer W, Chen KS, Gage FH, et al. Progressive decline in spatial learning and integrity of forebrain cholinergic neurons in rats during aging[J]. Neurobiol Aging, 1992,13(1):9-23.
[92]AndreasK. Functional neuroimaging in Alzheimer's type dementia.J Neurol Sci,2002,203;247-251.
[93]万晓珊.老年性痴呆的病理特征与防治对策[J].医学与社会,2006,19(12)：13-14.
[94]Forloni G Chiesa R, Smiorldo S, et al. Apoptosis mediated neuro toxieity induced by chornic application of beat amyloid fragament 25-35[J].Neuroreport,1993, 4:523-526.
[95]Loo DT Copani A, pike CJ, et al. Apopotsis is induced by beta amyloid incultured central nevorus system neurons[J]. Proc Natl AcadSci. USA,1993,90:7951-7955.
[96]S Wolf gang, J M contreras, P istabelle, et al. Structure based 3DQSAR and design of novel acetylcholinesteras inhibitors [J]. Comput Aided Mol Des,2001,15:395-410.
[97]Tabaton M. Ultrastructural localization of β-amyloid tau and ubiduitin epitopes in extracellular neurofibrillary tangles[J]. Proe Natl Acad sci USA,1991, 88:2098-2102.
[98]Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease[J]. Brain Pathol.1996,6(4):493.
[99]李学坤,左萍萍. Alzlleimer病中p淀粉样蛋白的毒性作用[J].国外医学·生理.病理科学与临床分册,2001,21(5)：363-365.
[100]Abe E, Casmaenti F, Giovannelli L, et al. Administration of amyloid β-petides into the medical septum of rats decrease acetycholine release from hippocmapus in vivo[J]. Brain Res,1994,636:162-164.
[101]Parameshwaran K, Dhanasekaran M, Suppiramaniam V Amyloid betapeptides and glutaxnatergic synaptic dysregulation[J]. Neurol,2007,24.
[102]Li F, Calingasan NY, Yu F, et al Increased plaque burden in brain of APP mutant MnSOD heterozygous knockout mice[J]. Neurochem,2004,89(5):1308-1312.
[103]Xie, H. Litersky, J.M., Hartigan, J.A. et al. The interrelationship between selective Tau phosphorylation and micro tubule association[J]. Brain Res,1998, 798(1-2):173-183.
[104]王哗,顾振纶,秦正红.蛋白质错误折叠与神经退行性疾病[J].中国临床神经科学,2005,13(4)：422-426.
[105]李静,周东华,王延红.海马注射p-淀粉样蛋白建立阿尔茨海默病大鼠模型的实验研究[J].中国临床神经科学,2008；16(5)：467-470.
[106]SasakiT, Kitagawa K, Yamagata K, et al.Amelioration of hippocampal neuronal damage after transient forebrain is-chemia in cyclooxygenase-2-deficient mice[J].Cereb BloodFlowMetab,2004,24(1):107-113.
[107]Chang SH, Liu CH, Conway R, et al Role of prostagand in E2 denpendent angiogenic switch in cyelooxgenase-2 induced breast cancer progression[J]. PNAS, 2004,101(2):591-596
[108]Lin MT, Lee RC, Yang PC, et al Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanismin human lung adenocarcinoma CLI.0 Cells, Invovement of phoshutioly liositol3-kinuse/Aktlathway[J]. Bio Chem,2001,276(52):48997-49002.
[109]陈莉芬,陶陶,余震等.阿魏酸钠对缺血缺氧致脑血管内皮细胞IκB-α、NF-κB表达的影响[J].第二军医大学学报,2007,29(1)：228-230.
[110]Bours V, Bentires-AljM, HellinAC, et al. Nuelear factor-kappa B, cancer, and apoptosis[J]. Bioehem 2000,60(8):1085-1089.
[111]Michael JM, SankarG-Signal transduction throngh NF-KB[J].Immunoloday,1998, 19:80-88.
[112]App Ieby SB, Ristimaki A, Neilson K, et al. Strature of the human cyclo-oxygenas-2gene [J]. Biochem,1994,302(Pt3):723-727.
[113]张世仪.一氧化氮与Alzheimer病[J].中国神经免疫学和神经病学杂志,2005,12(1)：29-30.
[114]韦道祥,陈俊抛.小胶质细胞与阿尔茨海默病[J]·国外医学·老年医学分册,2000,11：248-250.
[115]苏丙.Ap致痴呆老龄大鼠模型海马MARCKS表达变化机制及中药调节作用研究[D]北京：北京中医药大学博士论文.2010.
[116]Simonian NA, Coyle JT. oxidative stress in neuro degenerative diseases[J]. Annu Rev pharmarol Toxieal,1996;36:83-106.
[117]Yan SD, chen X, Fu J, et al RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease[J]. Nature,1996:382(6593):685-91.
[118]Harris ME, Hensley K, Butterfiexd A, et al. Direct evidence of oxidative injury produced by the Alzheimer'sβ-amyloid PePtide(1-40)in cultured hippocampal neurons[J].ExP Neurol,1995;131:193
[119]Marcus D, Thomas C. Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease[J].Exp Neurol,1998:150(1):40-4.
[120]Hensley K, Hall N, subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of Protein oxidation[J]. Neuroehem,1995:65(5):2146-56.
[121]Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells fromvfamilial Alzheimer's Patients[J]. Free Rad. Bio Med.2002(33):1372-1379.
[122]Butterfield D. A, Jennifer D, Chava P, et al. Evidence of oxidative damage in Alzheimer's disease brain:central role for amyloid beta-peptide[J]. Trends Mol. Med,2001,7(12):548-554.
[123]Vina J, Loret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants:prevention of oxidative stress[J]. Mol Aspects Med,2004, 25:117-123.
[124]smith Perry G, Riekey P, et al. Oxidative damage in Alzheimer's[J]. Nature, 1996:382(6587):120-131.
[125]Polidori MC. Oxidative stress and risk factors for Altheimer's disease:clues to prevention and therapy[J]. Alzheimers Dis,2004;6(2):185-91.
[126]Migliorea L, Fontanaa 1, Colognatoa R, et al. searching for the role and the most sultable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases[J]. Neurobiology of Aging,2005;26:587-595.
[127]张益,叶燕,唐秦.阿托伐他汀对阿尔茨海默病患者血清SOD、MDA和OX-LDL的影响[J].重庆医学,2009,38(12)：1527-1528.
[128]裘晟 姜黄素改善小鼠学习记忆能力及神经保护作用的机制研究[D].暨南大学硕士学位论文,2007.
[129]Fassbender K, Masteers C, Beyreuther K. Alzheimer's disease:molecular concepts and therapeutic targets[J]. Neurology,2001,55(6):865-877.
[130]John ER. Psychobiology[M]. New York:Academic Press.1971,199-200.
[131]刘梅,杨胜利.乙酰胆碱及其受体的非神经递质作用和肿瘤肿瘤学[J].2006,01：105-108.
[132]Miyazawa A, Fujiyoshi Y, Unwinn. Structure and gating mechanism of the acetylcholine receptor pore[J]. Nature,2003,423:949-955.
[133]Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders[J]. Psyc hop har macol,2004, 18:457-474.
[134]徐江平,刘传绩.中枢烟碱受体与阿尔茨海默病[J].中国药理学通报,1995；11(1)：9-12.
[135]Nilsson L, Nordberg A, Hardy J, et al. Physostigmine restores 3H-acetylcholine from Alzheimer's brain sclices to normal level[J]. Neuro Trans,1986:67:275-279.
[136]Dekosky S. Upregulation of choline acetyltransefrase activity in hippocampus and frontal cortex of elderly subjects with mildcognitive impairment[J]. Ann Neurol, 2002,51(2):145-155.
[137]Caldeorn FH, Bernhard R, et al. Toxic effets of aceytlcholinesterase on neuronal and glial-like cells in vitor[J]. Mol Pyschiarry,1998,3(3):247-255.
[138]Nelson T J Alkon D L. Oxidation of cholesterol by amyloid precursor production and Fibril Formation to a Much Larger Extent than Necrotic-like Death in CGNs[J]. Alzheimer's Dis 2007,12(3):211-220.
[139]Berson A, Knobloch M, Hanan M, et al. Changes in readthough acetylcholinesterase expression modulate amyloid-beta Pathology[J]. Brain,2008,131(Ptl):109-119.
[140]Auld D S, Komeccook T J, Bastianetto S, et al. Alzheimer's' disease and the basal forebrain cholinergic system:relation to beta-amyloid peptides, cognition, and treatment strategies[J]. Prog Neurobiol,2002,68(3):209-245.
[141]Colom IV Diaz ME, Beers DR, et al. Role of potassium channels in amyloid-induched cell death [J]. Neuorchem,1998,70:1925-1934.
[142]Morris RGM, Development of a water maze procedure for studying;spetial learning in the rat [J].Neurosci Meth,1984, 11(1):47-60.
[143]袁德培.补肾活血化痰方对胆碱能损伤痴呆大鼠作用的分子机制研究.湖北中医学院博士研究生论文,2004.
[144]李文德,吴玉娥,阂凡贵.恒河猴大脑注射Aβ1-42和Thiorphan对胆碱能神经元影响的研究[J].基础医学,2009,23：7-10.
[145]牛丰南,孙宗正.阿尔茨海默病早期诊断的分子靶标研究进展(J).国际神病学神经外科学杂志,2009；36(1)：86-90.
[146]姚洁,王培昌.脑脊液生物学标志物的检测在阿尔茨海默病诊断中的应用(J)中国老年学杂志,2007；27(16)：1631-5.
[147]许国旺,路鑫,杨胜利.代谢组学研究进展[J].中国医学科学院学报,2007；29(6)：701-11.
[148]艾斯克尔·吐拉洪,哈木拉提·吾甫尔,巴吐尔·买买提明等.基于NMR的维吾尔医异常黑胆质型肿瘤患者血浆代谢组学分析[J].科技导报2009,27(13)27-29.
[149]王红强,马艳,马晓慧.新疆和田地区667例60岁以上老人长寿影响因素分析[J].热带医学杂志,2011,10：73-76.
[150]Alzheimer's Disease International World Alzheimer Report[R]. London, United Kingdom:King's College,2009.
[151Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease[J]. Alzheimers Dement 2008;4:65-79.
[152]Hong YK, Park SH, et al., Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease[J]. Ethnopharmacol.2011,134(3):1028-1032.
[153]Jeon S, Bose S, Hur J, et al. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease[J]. Ethnopharmacol.2011,137(1):783-9.
[154]徐月英.系统论原理在中医证研究中的运用[J].医学与哲学(人文社会医学版),2006,27(7)：65-66.
[155]李继明.证的主观性与客观性[J].成都中医药大学学报,2006,29(3).
[156]沈自尹.系统生物学和中医证的研究[J].中国中西医结合杂志,2005,25(3)：225-228.
[157]洪玉.新疆维汉两民族阿尔茨海默病的分子流行病学研究[D].乌鲁木齐：新疆医科大学博士论文.2008.
[158]哈木拉提·吾甫尔,阿不都热依木·玉素甫,努尔买买提·艾买提.异常黑胆质新论[M].新疆科学技术出版社,2010.
[159]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220.
[160]何彦丽,应逸,许艳丽等.杞多糖对荷瘤小鼠肿瘤微环境T淋巴细胞亚群及树突状细胞的影响[J].中西医结合学报,2005,3(5)：374-376.
[161]穆哈穆德.艾克拜尔,艾尔扎尼主编.米扎尼提普(波斯文)[M]：拉合尔伊斯兰出版社,1344年(农历)：85-92.
[162]斯依提.穆哈穆德.候赛音主编.麦合孜尼艾地维亚(草药宝库)(波斯文)[M]：印度吉维力可西瓦出版社.1988,251-292.
[163]姜波,严妍,吴娟芪归健脑颗粒对老年性痴呆大鼠学习记忆及脑组织nNOS、COX-2蛋白表达的影响[J].江苏大学学报(医学版)2009,05：21-24.
[164]Du Y, Wooten M C, and Wooten M W. Oxidative damage to the promoter region. of SQSTMl/p62 is common to neurodegenerative disease[J]. Neurobiol Dis,2009. 35(2):302-310.
[165]Bennett S, Grant M M, and Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease:a commonpathology[J]. Alzheimers Dis,2009.17(2):245-257.
[1]MichaelisML. Drugs targeting Alzheimers disease:some things old and some things new[J]. PharmacolExpTher,2003,304(3):897-904.
[2]庄莹,陈杰.阿尔茨海默病病因及发病机制研究进展[J].吉林医药学院学报,2008,29(4)：101-103.
[3]郭蕾,王永炎,张志斌.关于证候概念的诠释[J].北京中医药大学学报,2003,26(2)：5-8.
[4]赵慧辉,王伟.病证结合证候模型研究基本思路[J].中华中医药杂,2006,21(12)：762-764
[5]吴同玉,高碧珍.病证结合动物模型的模式探讨[J].中国中医药信息杂志,2009,12(16)：6-7.
[6]高冰冰,徐淑萍,刘新民,王立为.开心散与去茯苓开心散改善拟AD动物学习记忆作用比较[J].中国比较医学杂志,2010,7(20)：57-61.
[7]LambertMP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent cen-tral nervous system neurotoxins[J]. Proc NatlAcAD SciUSA,1998,95(11):6448-6453.
[8]Kayed R, HeAD E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies commonmechanism of pathogenesis[J]. Science,2003,300(5618): 486-489.
[9]代建峰,高建青,方三华.不同治法对老年性痴呆大鼠脑组织海马CA1区椎体细胞的影响[J].中国中医药科技,2009,7(16)：302-303.
[10]牛英才,周丽,张晓杰.加减地黄饮子对阿尔茨海默病大鼠模型的实验研究[J].陕西中医药,2007,5(28)：620-621.
[11]周龙岗,张志慧.通心络对β-淀粉样蛋白脑室注射所致阿尔茨海默病模型大鼠干预作用研究[J].络病学基础与临床研究,2006,(5)：52-53.
[12]张雪飞.氯化铝中毒小鼠不同脑区M受体含量的比较观察[J].青海医学院学报,2002,23(1)：10-12.
[13]焦俊英贾成文,等.醒脑增智方对AD鼠GSH-PX、SOD、MDA影响的实验研究[J].陕西中医,2006,27(6)497-498.
[14]张妍,林青,唐民科,等.复方丹参对老年痴呆模型大鼠海马和大脑皮层ChAT、 AchE活性的影响[J].北京中医药大学学报,2008,31(3)：192-195.
[15]张晓裕,何利明,侯军代,等.去痴灵对AD模型小鼠学习记忆及脑内突触体素表达的影响[J].中国老年学杂志,2010,30(4)：495-498.
[16]胡利,吴正治.疏肝解郁法对老年性痴呆模型神经细胞凋亡的机理研究[J].中医药导报,2010,16(7)：1-3.
[17]胡玉萍,袁德培.千层塔合剂对AD模型大鼠学习记忆能力及细胞凋亡的影响[J].辽宁中医杂志,2009,36(19)：1807-1810.
[18]吴同玉,高碧珍.病证结合动物模型的模式探讨[J].中国中医药信息杂志,2009,12(16)：6-7.
[19]陈向良,袁长津,袁梦石.损伤杏仁核制备阳虚阿尔茨海默病大鼠模型[J].中国老年学杂志,2007,27(1)：137-138.
[20]阎玥,王桐生,等.肝郁脾虚证模型大鼠HPA轴中枢相关受体的表达及疏肝健脾方药的干预作用[J].上海中医药杂志,2010,44(2)：58-60.
[21]王桐生,谢鸣.肝郁模型大鼠行为学与脑单胺递质的变化及柴胡的干预作用[J].中华中医药杂志,2008,10(23)：934-935.
[22]战丽彬,徐枫,董玉宽,等.滋补脾阴方药对老龄大鼠脑线粒体膜ATP酶活性的影响[J].中药药理与临床2000,16(1)24-25.
[23]李明陈,嫚茵,吴正治.补肝养髓方对老年性痴呆模型皮质神经元RNA和Nissl体的定量研究[J].深圳中西医结合杂志,2007,6(17)：136-137.
[24]游龙武,吴正治,李明.补肝养髓方对自发老年性痴呆模型神经信使分子一氧化氮代谢的影响[J].中国临床康复,2004,8(19)：3846-3847.
[25]刘志承,吴正治,李明.补肝养髓方对自发老年性痴呆模型中枢胆碱能系统活性的影响[J].中西医结合心脑血管病变,2004,7(2)：402-403.
[26]吴正治,张艳萍,王怀龄.补肝养髓方对自发老年性痴呆模型氧自由基损伤的定性定量研究[J].中国中医药科技,2007,11(7)：442-443.
[27]吴正治,李映红,李明.补肝养髓方对自发老年性痴呆模型突触可塑性的电镜定量研究.中国中医药科技,2007,11(6)：444-445.
[28]田金洲,杨承芝,盛彤,等.可疑痴呆人群中阿尔茨海默病临床前的认知损害及其与中医证候的关系[J].湖北中医学院学报,1999,11(4)：49-55.
[29]宋彩梅,王红梅.肾虚型老年痴呆动物模型的建立[J].现代中西医结合杂志,2011,22(8)：2744-2745.
[30]周乐全,丁胜元.阴虚对老年模型大鼠学习记忆的影响[J].广州中医药大学学报,2001,18(3)：57-59.
[31]陈京萍,周乐全.六味地黄汤对老年阴虚大鼠学习记忆能力的改善作用[J].中药新药与临床药理,2001,12(7)：282-283.
[32]黄兆胜,孙维广.养寿丹对阿尔茨海默病肾阳虚模型大鼠学习记忆的影响[J].中成药,2002,24(2)：113-114.
[33]刘明平,黄兆胜.养寿丹对Alzheimer病肾阳虚模型大鼠中枢胆碱能神经递质和细胞因子的影响[J].中国实验方剂学杂志,2003,9(10)：19-20.
[34]尚冰,李德新.脾气虚证、脾阴虚证、脾阳虚证模型大鼠MDA、SOD、GsH-Px、 T-AOC、8-OHdG、端粒长度变化的实验研究[D].辽宁中医药大学博士论文,2006.
[35]王彩霞林庶茹.Alzheimer型痴呆大白鼠病证结合模型的实验研究[J].辽宁中医杂志,1998,25(3)：141-142.
[36]王彩霞,李德新,等.理脾阴正方提高Alzheimer痴呆模型动物学习记忆能力的机理探讨[J].辽宁中医杂志,2002,29(4)：242-243.
[37]战丽彬,刘莉,宫晓洋,等.脾阴虚痴呆证病结合模型建立及滋补脾阴方药对其影响的实验研究[J].中华中医药学刊,2008,26(2)：9-12.
[38]战丽彬,宫晓洋,等.脾阴虚痴呆大鼠不同脑区Snk-SPAR路径及滋补脾阴方药调控作用研究[J].世界科学技术-中医药现代化.中医研究,2011,13(5)836-841.
[39]战丽彬,刘莉,等.滋补脾阴方药对脾阴虚痴呆大鼠海马蛋白质组学影响的研究[J].世界科学技术-中医药现代化.中医研究,2011,13(3)480-486.
[40]史宏,张静.茵陈五苓散提高痴呆小鼠脑组织抗氧化能力的实验研究[J].广西中医药,2009,1(32)：55-56.
[1]阿吉·阿布里米提,玉素甫,主编.维吾尔医学基础理论[M].乌鲁木齐：新疆人民卫生出版社,1988：114-144.
[2]南京中医药大学总编审.中华本草维吾尔医药卷[M]；上海科学技术出版社,2005,12(1)：101-176.
[3]阿依努尔·买提斯迪克,尼加提·热合曼,哈木拉提·吾甫尔.等异常黑胆质证候模型下丘脑-垂体-肾上腺轴组织形态学观察[J],新疆医科大学学报2005(28)10：907-908.
[4]阿依努尔·买提斯迪克,尼加提·热合曼,哈木拉提·吾甫尔.等异常黑胆质证候模型下丘脑-垂体-肾上腺轴组织形态学观察[J],新疆医科大学学报2005(28)10：908-909.
[5]努尔买买提.艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究[D].博士论文.2007.
[6]阿依努尔·买提斯迪克,胡汉华,哈木拉提·吾甫尔,等.异常黑胆质证候模型支配器官组织细胞超微结构观察[J].新疆医科大学学报2005(28)10：912-914.
[7]TanZ, NagataS. PVNc-fos expression, HPA xis response and immune cell distribution during restraistress. JUOEH,2002,24(2):1312149.
[8]BrattAM, KelleySP, KnowlesJP, et al. Longterm modulation of the HPA axis by the hippocampus. Behaioral, biochemical and immunological endpoints in rats exposed to chronic mild stress[J]. Psychoneuroendocrinolgy,2001,26(2):121-145.
[9]SimpkissJL, DevineDP. Responses of the HPA axis after chronic variable stress:effects of novel and famili stressors[J].NeuroEndocrinol,2003,24(122):97-103.
[10]哈木拉提·吾甫尔.维吾尔医气质、体液伦及其现代研究[M].乌鲁木齐：新疆科学技术出版社,2003.152-153.
[11]哈木拉提·吾甫尔,阿不都热依木·玉苏甫,吐尔逊·吾甫尔.维医异常体液分型与年龄、性别关系的探讨[J].中国民族民间医药杂志,2003,(61)：84-86.
[12]徐卫方,哈木拉提·吾甫尔等异常黑胆质与肾虚痰瘀的关系研究[J].新疆医科大学学报,2005,28(4)：300-304.
[13]阿不都热依木·玉素甫,李林,哈木拉提·吾甫尔等.维医异常体液分型及其与氧化-抗氧化系统关系的研究[J].中国中医基础医学杂志,2004,10(8)：61-62.
[14]努尔买买提·艾买提,哈木拉提·吾甫尔,阿依努尔·买提斯迪克.异常黑胆质载体动物模型免疫学本质的研究[J].中国中医基础医学杂志,2006,12(12)：903-905.
[15]阿依努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提·艾买提,等.异常黑胆质证载体动物模型的建立及其自然恢复反证[J].新疆医科大学学报,2006,29(10)：910-914.
[16]阿衣努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提·艾买提,等.异常黑胆质载体动物饮食量和饮水量的观察[J].新疆中医药,2006,24(1)：5-7.
[17]哈木拉提·吾甫尔,阿依努尔·买提斯迪克,努尔买买提·艾买提等.维医异常黑胆质证载体动物模型的评价[J].中国中医基础医学杂志,2007,13(3)：186-188.
[18]尼加提·热合木,阿依努尔‘买提斯迪克,哈木拉提·吾甫尔等.异常黑胆质载体动物模型支配器官的组织形态学改变[J].新疆医科大学学报,2006,29(10)：917-918.
[19]阿依努尔·买提斯迪克,胡汉华,哈木拉提·吾甫尔等.异常黑胆质载体动物模型支配器官组织细胞超微结构观察[J].新疆医科大学学报,2006,29(10)：919-921.
[20]Jacob Raber, Susan F. Akana, Seema Bhatnagar, et al. Hypothalamic-Pituitary-Adrenal Dysfunction in Apoe-/-Mice:Possible Role in Behavioral and Metabolic AlterationsThe Journal of Neuroscience, March 1,2000,20(5):2064-2071.
[21]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提等.维吾尔族异常黑胆质型患者基因多态性研究[J].中华医学遗传学杂志,2003,20(1)：77-78.
[22]哈木拉提·吾甫尔.维吾尔医学气质、体液论及其现代研究[M].新疆科技术出版社,2003,7：75-77.
[23]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提等.ApoE基因多态型与维吾尔族高血压患者的关系[J].中国免疫学杂志2003,Vol.19：108-110.
[24]哈木拉提·吾甫尔,艾斯卡尔‘依米提,伊力哈木江‘沙比提,等.ApoE基因多态性与异常黑胆质型疾病的关系[J].中华医学遗传学杂志,2003,20(6)：549-550.
[25]努尔买买提.艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究.乌鲁木齐：新疆医科大学博士论文.2007.
[26]D. A. Dubrovin.异常黑胆质型ApoE-ko动物的模型建立.维吾尔医药及其他传统医学研究与应用[C].新疆乌鲁木齐.2003.6.乌鲁木齐.新疆人民卫生出版社.2007：10-13.
[27]沙吉旦·阿不都热衣木,金伟,热娜古丽等.复杂性疾病血栓前状态指标变化的共性研究[J].科技导报,2007,24(20)：66-69.
[28]张莉,哈木拉提·吾甫尔,胡尔西旦等.异常黑胆质载体动物肿瘤模型的建立及其神经内分泌免疫指标的改变[J].国际病理科学与临床杂志2007(5)：963-966.
[29]张莉,哈木拉提·吾甫尔,玛依努尔等.恶性肿瘤的维医分型及其神经内分泌免疫网络紊乱研究[J].中国中医基础医学杂志2008,24(2)：220-223.
[30]哈木拉提·吾甫尔,李风森,杨剑等.西医重度哮喘、中医虚哮型哮喘和维医异常黑胆质哮喘的交互性研究[J].科技导报,2008,8(6)：45-49.
[31]Sajida Abdureyim, Nurmuhammat Amat, Anwar Umar, et al. Anti-inflammatory, immuno-modulatory and heme oxygenase-1 inhibitory activities of Ravan Napas, a formulation of Uighur Traditional Medicine, in a rat model of allergic asthma[J]. Evidence-based Complementary and Alternative Medicine,2010.221-223.
[32]克丽别娜·吐尔逊,伊力哈木·沙比提,王雯等.维医异常黑胆质性哮喘β_2AR基因多态性研究[J].新疆医科大学学报,2007,(09)：88-90.
[33]艾尼瓦尔·卡德尔,哈木拉提,庞辉群.新疆维族夜间哮喘发作期患者维吾尔医辨证分型特点分析[J].中国民族医药杂志,2000,6(4)：29-30.
[34]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220
[35]邓云华,陈映玲,陈兴平等.介菌多糖核酸、胸腺肽影响正常和免疫抑制[J].中华医学实践杂志,2003,2(1)：21.
[36]阿布都热依木.玉苏甫.异常黑胆质成熟剂对HepG2细胞及其相关基因表达的影响.乌鲁木齐：新疆医科大学博士论文,2005.
[37]努尔买买提,哈木拉提·吾甫尔.异常黑胆质成熟剂和清除剂对小鼠神经内分泌免疫网络的调节作用.维吾尔医学及其他传统医学的研究与应用[C].乌鲁木齐：新疆人民卫生出版社2003：11-12.
[38]邹浩军,明亮.黄酮类化合物抗炎免疫及抗衰老药理研究进展[J].安徽卫生职业技术学院学报2003,3(6)48-50.
[39]Abdiryim Yusup, Halmurat Upur, Xirali. The effect of Abnormal Savda Munziq total flavonoids on the proliferation, apoptosis and correlative gene expression in human hepatoma(HepG2)cells[J]. Toxicology Letters,2006.164S-S250
[40]Abdiryim Yusup, Halmurat Upur. Protective effects of Abnormal Savda Mushil to mitochondrial oxidative damage[J]. Free Radical Biology and Medicine, 2002;33(1):s240-s240.
[41]Abdiryim· yusup, Halmurat·upur. Isabelle Baudrimont Cytotoxicity of abnormal savda munziq inhibition of cell growth and DAN, protein synthesis in HEPG2 cells[J]. Toxicology and applied pharmacology,2004.690-692.
[42]许士凯,王晓东,赵军宁等天然药物抗衰老有效成分研究进展(之三)[J].现代中西医结合杂志2005,14(21),2773-2775.
[43]魏巍.中药甙类活性成分抗辐射作用的研究[J].中国辐射卫生2006,15(2)251-252.
[44]刘颖,金宏,程义勇.多糖生物活性及其作用机制研究进展[J].中国公共卫生2006,22(5)627-629.
[45]林旭凯,陈文玲,李盛鹏,等.复方活性多糖对实验大鼠免疫调节作用研究[J].现代预防医学,2004,31(4)：509-510.
[46]穆哈穆德·艾克拜尔,艾尔扎尼主编.米扎尼提普(波斯文)[M]：拉合尔伊斯兰出版社,1344年(农历)：85-92.
[47]哈木拉提·吾甫尔,努尔买买提·艾买提.异常黑胆质载体动物模型的下丘脑-垂体-肾上腺轴功能紊乱的物质基础研究[J].中国中医基础医学杂志,2007(13)9：125-128
[48]努尔买买提·艾买提,哈木拉提·吾甫尔,阿迪力等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴的调节作用研究[J].时珍国医国药,2007(11)：69-71.
[49]阿地力江·阿不力米提.哈木拉提·吾甫尔.胡汉华等.异常黑胆质成熟剂对异常黑胆质载体动物模型支配器官细胞超微结构的影响[J].中国中医基础医学杂志,2008 14(1)：129-131.
[50]Halmurat Upur, Anwar Umar, Adil Ablimit, et al. Effect of Abnormal Savda Munziq on morphological and ultrastructural changes of target organs in an Abnormal Savda syndronme animal model[J]. Fundam Clin Pharmacol,2007,21(l):69-69.
[51]Halmurat Upur, Anwar Umar, Adil Ablimit, et al. The effect of Abnormal Savda Munziq on morphological and ultrastructural changes of hypothalamus[J]. Fundam Clin Pharmacol,2007,21(1):74-74.
[52]Nurmuhammat Amat, Halmurat Upur, Adiljan Ablimit, et al. Immunomodulatory combined stress mice[J]. Journal of Ethnopharmacology,2009,122(1):42-47.
[53]Batur mamtimin, Halmurat upur, Fu-hua, Aynur matsidik and Rena Rahim. Plasma magnetic resonance vevealing the relationship of different tumor and the disease homology theory of traditional Uyghur medicine. Chinese journal of integrative Medicine,2011(17)2:111-115.
[54]Peiyuan Yin, Patamu Mohemaiti, Jing Chen, et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry[J]. Journal of Chromatography B,2008, Vol 871, (2):322-327.
[55]阿布都艾尼,阿不都热依木·玉苏甫,哈木拉提等.异常黑胆质成熟剂和清除剂对OH.引发的DNA损伤的保护作用[J].中药药理与临床,2000；16(3)：34-36.
[56]Abdiryim Yusup, Halmurat U, Umar A, et al. Protective effects of Munziq and Mushil of Abnormal Savda to mitochondrial oxidative damage[J]. Fundam Clin Pharmacol 2004;18(4):471-6.
[57]哈木拉提,阿不都热依木,阿布都艾尼等.维吾尔医成熟剂和清除剂抗活性氧的作用研究[J].中国民族医药杂志,2000,6(3)：30-32.
[58]沙吉旦·阿不都热衣木,金伟,热娜古丽·艾则孜等.复杂性疾病血栓前状态指标变化的共性研究[J].科技导报,2007,12(200)：120-123.
[59]艾斯卡尔·伊米提,哈木拉提·吾甫尔,布再娜甫·伊力哈木.维吾尔医成熟剂和清除剂诱导T淋巴瘤细胞凋亡的研究[J].中国药理与临床,2000,16(2)：33-34.
[60]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提.异常黑胆质成熟剂与清除剂对人Hela细胞凋亡基因表达的影响[J].细胞与分子免疫学杂志,2001,17(2)：109-111.
[61]Abdiryim Yusup, Halmurat U, Umar A, et al. Protective effects of Munziq and Mushil of Abnormal Savda to mitochondrial oxidative damage[J]. Fundam Clin Pharmacol,2004,18(4):471-6
[62]Nurmuhammat Amat, Halmurat Upur, Biljana Blazekovi'c. In vivo hepatoprotective activity of the aqueous extract of Artemisia absinthium L. against chemically and immunologically induced liver injuries in mice[J]. Journal of Ethnopharmacology, 2010,131,478-484
[63]Halmurat Upur, Nurmuhammat Amat. Protective effect of Cichorium glandulosum root extract on carbon tetrachloride-induced and galactosamine-induced hepatotoxicity in mice[J]. Food and chemical toxicology,2009.123-126
[2]吴思缈,周黎明.阿尔茨海默病的发病机制及药物治疗的进展[J].四川生理科学杂志,2009,31(1)：36-39.
[3]Ferfi Cp, prince M, Bmyne C, et al. Global prevalence of dementia:a Delphi consensus study[J]. Lancet,2005,366:2112-2117.
[4]Alzheimer Disease Iniernational. alzCO. uk/researeh/statistics. html accessed on 2007-5-16.
[5]Alzheimer's Association.2009Alzheimer disease facts and figures[J] Alzheimers Dement,2009,5(3):234-270.
[6]Gorelick PB. Preventable Dementia[J]. New York:Oxford University Press,2003, 308-320
[7]Sujuan Gao, Hugh C, Hendrie, et al. The Relationships Between Age, Sex, and theIncidence of Dementia and Alzheimer Disease:A Meta-analysis[J]. Arch GenPsychiatry.1998;55:809-815.
[8]Sterling C, Andrew J, Leslie C, et al. The Relationship between fMRI Activation andCerebral Atrophy:Comparison of Normal Aging and Alzheimer Disease[J].2000, 11(3):179-187.
[9]Frisoni GB, Fratiglioni L, Fastbom J, et al. Mild cognitive impair-ment in thepopulation and physical health:data on 1435 individuals aged 75 to 95[J]. Gerontol A Biol Sci Med Sci,2000,55:M322-328.
[10]Tschanz JT, Corcoran C, Skoog I, et al. Dementia:the leading predictor of death in a defined elderly population:The Cache County Study[J]. Neurology,2004,62:1156-1162.
[11]Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synihetic amyloid betapeptide:isoform-speeific effects and imPlieations for late6onset Alzheimer disease. Proe Natl Aead SciUSA,1993,90(17):8098-8102.
[12]Sub GH, SharaA. A Review of the epidemiological transition in dementia:cross national comparisons of the indices related to Alzheimer, disease and vaseular dementia[J]. Acta psychiatry scand,2001,104(2):4-11.
[13]Anthony H, Vagnucci JR, William W Li. Alzheimer's disease and angiogenesis[J]. Lancet,2003,361:605-608.
[14]Forette F, Seux ML, Staessen JA, et al. The prevention of dementia withantihypertensive treatment:new evidence from the Systolic Hypertension inEurope(Syst-Eur)Study[J]. Arch Intern Med,2002,162:2046-2052.
[15]Tian J. Dementia in Asian Context. In:The Cambrige Handbook of Age and Ageing, eds. Malcolm Johnson. Cambridge University Press,2005,261-274.
[16]MichaelisML. Drugs targeting Alzheimers disease:some things old and some things new[J]. JPharmacolExpTher,2003,304(3):897-904.
[17]陈美婉,罗焕敏,肖飞等.秋水仙素诱导的神经元突起溃变对Ap分泌的影响[J].中国药理学通报,2008,12：51-56.
[18]Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease:progressand Problems on the road to the ropeuties[J]. Science,2002,297(5580):353-356.
[19]Mayeux, R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci,2003, 26:81-104.
[20]洪玉,周晓辉,马龙.新疆维汉两民族阿尔茨海默病A2M基因多态性分析[J].中国神经精神疾病杂志,2008,(06)334-337.
[21]Pappolla MA, Sos M, Omar RA, et al. Melaton in prevents death of neuro-blastoma cellsexposed to the Alzheimer amyloid peptide[J]. Neurosci,1997,17:1683-1690.
[22]Drouet B, Fifre A, Pincon RM, et al. ApoE protects cortical neurons against neurotoxicity induced by the nonfibrillar C-terminal domain of the amyloid-beta peptide[J]. Neurochem,2001,76(1):117-127.
[23]Haass C. Amyloidβ-Peptide is Produced by cultured cells during normal metabolism[J]. Nature,1992,359:322-325.
[24]hojiM. Production of the Alzheimer amyloid P-Protein by normal Proteolytic Processing[J]. Seienee,1992,258:126-129.
[25]Silkoe DJ. Alzheimersdisease:genesProtein, and therapy[J]. PhysiloRv,2001, 81(2):741-766.
[26]RogerN, Rosenberg MD. Translational research on the way to effective therapy for Alzheimer disease[J]. Aich Gen Psychiatry,2005,62(11):1186-1192.
[27]Mayeux, R. Epidemiology of neurodegeneration[J]. Annu Rev Neurosci,2003, 26:81-104.
[28]张惠淑,林群,杨东辉.阿尔茨海默症中Ap毒性机制研究进展[J].中国当代医.药,2009,09：29-30.
[29]张忠立,左月明.黑水缬草对老年痴呆模型大鼠脑内iNOS、COX-2和IκB-α表达的影响[J].中药材,2010,33(4：)：581-583.
[30]Itoh A, Nitta A, Nadai M, et al. Dysfunetion of cholinergic and dopainergic neuronal systems in beta-amyloid protein-infused rats[J]. Neurochem,1996, 66(3):1113-1117.
[31]Muir JL. Acetylcholine aging and Alzheimer's disease[J]. Pharmacol Biochem Behav,1997,56:687-696
[32]Auld DS, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic neuromdulators:A missing link Trends[J] Neurosci,1998,21:43-49.
[33]W illiams TI, Lynn BC, MarkesberyWR, et al. Increased lev-els of 4-hydroxynonenal and acrolein, neurotoxic markers oflipid peroxidation, in the brain in mild cognitive impairmentand early Alzheimer's disease. Neurobiol Aging, 2006,27(8):1094-1099
[34]Velenzuela M J, Sachdev P. Magnetic resonance spectroscopy in AD [J]. Neurology,2001,56(5):592-598.
[35]Garcias J M, Gavrila D, Antunez C,et al. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey[J]. Dement Geriatr Cogn Disord,2008, 26 (1):15-25.
[36]. Chna SL. Furukawa K, Mastton MP Presenilins and APP in neuritic and synaptic plasticity:implications from the pathogenesis of Alzheimer's disease[J]. Neuromolecular Med,2002,2:167-196
[37]宋琳,谢宁.地黄饮子改善痴呆大鼠学习记忆及其防治AD作用机理的实验研究[D],黑龙江：黑龙江中医药大学博士学位论文,2005,5.
[38]郭蕾,王永炎,张志斌.关于证候概念的诠释[J].北京中医药大学学报,2003,26(2)：5-8.
[39]赵慧辉,王伟.病证结合证候模型研究基本思路[J].中华中医药杂志2006；21(12)：762-764.
[40]热娜古丽,沙吉达,哈木拉提等.复杂性疾病异常黑胆质证及其血栓前状态的研究[J].中国中医基础医学杂志,2008,14(8)：614-615.
[41]阿不都热依木,阿衣木姑,哈木拉提.吾甫尔等.维医异常体液型冠心病与ACE、eNOS、FVII及ICAM-1基因多态性关系的研究[J].科技导报,2009,27(5)：19-27.
[42]哈木拉提.吾甫尔,阿不都热依木.玉苏甫,吐尔逊.吾甫尔.维医异常体液分型与年龄、性别关系的探讨[J].中国民族民间医药杂志,2003,61：84-86.
[43]哈木拉提.吾甫尔：维吾尔医气质、体液论及其现代研究[M].新疆：新疆科学技术 出版社,2003：34-38
[44]阿依努尔.买提斯迪克,胡汉华,哈木拉提.吾甫尔等.异常黑胆质载体动物模型支配器官组织细胞超微结构观察[J].新疆医科大学学报.2006,29：919-920.
[45]阿依努尔.买提斯迪克,尼加提.热合曼,哈木拉提.吾甫尔.异常黑胆质载体动物模型下丘脑—垂体—肾上腺轴组织形态学观察[J].新疆医科大学学报,2006,29：914-916.
[46]阿吉.阿布里米提,玉素甫,主编.维吾尔医学基础理论[M].乌鲁木齐：新疆人民卫生出版社,1988：114-144.
[47]木拉提.克扎衣别克,刘波.异常黑胆质成熟剂化学成分初步研究[J].时珍国医国药,2010,21(12)：3139-3141.
[48]努尔买买提,哈木拉提,阿迪力等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴的调节作用研究[J],时珍国医国药,2007,18(11)：2601-2603
[49]阿不都热依木,哈木拉提,斯拉甫等.异常黑胆质清除剂对线粒体氧化损伤的保护作用[J].中国中医基础医学杂志,2002,8(7)：38-40.
[50]阿地里江.阿不力米提,胡汉华,艾来提.米吉提等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴细胞超微结构的影响[J].国际病理科学与临床杂志,2007,27(3)：185-191.
[51]艾来提·米吉提,阿地里江·阿不力米提.维医异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴形态学的影响[J].国际病理科学与临床杂志,2008,28(1)：6-9.
[52]哈木拉提,阿不都热依木.维吾尔医成熟剂和清除剂抗活性氧的作用研究[J].中国民族医药杂志,2000,7(6)3：30-32.
[53]阿布都艾尼,阿不都热依木,哈木拉提等.异常黑胆质成熟剂和清除剂对OH·引发的DNA损伤的保护作用[J].中药药理与临床,2000,16(3)：34-36.
[54]阿布都艾尼,阿不都热依木.异常黑胆质成熟剂和清除剂对OH·引发的DNA损伤的保护作用[J]中药药理与临床2000；16(3)33-35.
[55]阿不都热依木.维医异常黑胆质成熟剂对HepG2细胞生长和凋亡及相关基因调控的研究[D].乌鲁木齐：新疆医科大学博士学位论文,2005.
[56]哈木拉提·吾甫尔,李林.异常黑胆质成熟剂与清除剂对氧化损伤的淋巴细胞p53蛋白表达的影响[J].新疆医科大学学报,2005,28(4)287-289.
[57]艾斯卡尔.依米提,哈木拉提.吾甫尔.维吾尔医成熟及清除剂诱导T淋巴瘤细胞凋亡的研究[J].中药药理与临床,2000；16(2)；33-34.
[58]阿不都热依木.玉苏甫.维医异常黑胆质成熟剂对HepG2细胞生长和凋亡及相 关基因调控的研究[D].乌鲁木齐：新疆医科大学,2005：121.
[59]阿不都热依木.玉苏甫,哈木拉提.吾甫尔等.异常黑胆质成熟剂黄酮类化合物诱导HepG2细胞凋亡机制的研究[J].中国中药杂志,2007,32(11)：1068
[60]Nurmuhammat Amat, Halmurat Upur, Adiljan Ablimit. Immunomodulatory effects of Abnormal SavdaMunsiq, a traditional Uighur medicine, on the combined stress mice[J], Journal of Ethnopharmacology,2009,122(1):42-47.
[61]梁妍琦,黄霄天,唐希灿.阿尔采末病发病机制及治疗药物研究进展[J].中国新药与临床杂志,2007,20(4)：641-648.
[62]张均田,石成璋,梅保幸等.“水迷宫”自动控制仪的研制及在神经药理研究中的应用[J].药物分析杂志,1991,11：23-26.
[63]阿依努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提‘艾买提等.异常黑胆质证载体动物模型的建立及其自然恢复反证[J].新疆医科大学学报,2006,29(10)：910-914.
[64]阿地力江,胡汉华,哈木拉提等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴细胞超微结构的影响[J].国际病理科学与临床杂志,2007,27(3)：185-191.
[65]依沙克江.穆罕穆德,主编.中国医学百科全书维吾尔医学分卷[M].第一册.乌鲁木齐：新疆人民卫生出版社.1985.
[66]Caroline. Beaufour, Nicolass Ballon. Efeects of chronic antidepressants in an Operant Confilic Procedure of Anxiety in the rat[J]. Pharmacology Biochemistry and Bahavior,1999,4(61):591-599
[67]Joao Palermo-Neto. Efeects of physical and psychological stressor on behavior and macrophage activity, and Ehrlich tumor growth[J]. Brain, Behavior and Immunity, 2003,(17)1:43-54.
[68]J. Kellet, extension deficit and fear reinstatement after electrical stimulation of theamygdale:implication for kindling-associated fear and anxiety[J]. neuroscience, 2004,127(2)277-287.
[69]哈木拉提·吾甫尔等.维吾尔医学气质、体液论及其现代研究[M].新疆科技术出版社,2003,7：75-77.
[70]陈小野.中医征候证候模型的制备方法概论[J].上海实验动物科学,1999,19(3)：191-193.
[71]刘晓伟,张红梅等.中医奴恐伤气证候模型制作及行为评估[J].2006,15(1)：10-11.
[72]Daniele Console, Julia Fedotova stressor affect the response of male and female rats to clomipramine in a model of behavioral despair[J]. European Journal of Pharma-cology,2005,520(1-3):100-107.
[73]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220.
[74]Jason Shumake, Douglas Barretr and F. Gonzalez-Lima Behavioral characteristics of rats predisposed to learned helplessness:Reduced reward sensitivity, increased novelty seeking, and persistent fear memories[J]. Behavioral Brain Research. 2005;165(2):222-230.
[75]George Paxinos, Charles Watson. The Rat Brain in Stereotaxic Coordinates[J]. Academic Press,1986:2.
[76]Morris RGM spatial localization does not require the presence of local cues[J] 1981 doi:10.1016/0023-9690(81)90020-5
[77]方福德.现代医学实验技巧全书.第一版.北京：北京医科大学和中国协和医科大学联合出版社[M],1995：420-425.
[78]张均田,张庆柱.神经药理研究技术与方法[M].北京：人民卫生出版社,2005,297-299.
[79]努尔买买提·艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究.乌鲁木齐：新疆医科大学博士论文.2007.1-3.
[80]雅森·米吉提,库热西·玉努斯,吐尔洪·吐送.维吾尔医学体液辩证分型及其相关疾病[J].新疆医科大学学报,2010.06：24-25.
[81]江维,哈木拉提·吾甫尔,吐尔洪·吐送等.维医异常黑胆质体液质高血压人群和正常黑胆质体液质健康人群肠道菌群多样性分析[J].中国病原生物学杂志,2012,02：58-62.
[82]阿地里江·阿布力米提.不同致病因素与异常黑胆质证候模型建立及其NEI网络和代谢组学的研究[D].新疆：新疆医科大学,2010：100-101.
[83]哈木拉提·吾甫尔.气质体液论及其现代研究[M].乌鲁木齐：新疆科技卫生出版社,2003.44-52.
[84]哈木拉提.维尔医学气质、体液论及其现代研究[M].乌鲁木齐：新疆科学技术出版社,2003,7：93-98.
[85]易沙克江.马合穆德,主编.中国医学百科全书维吾尔医学分卷,第六册[M].乌鲁木齐：新疆科技卫生出版社,1995,第一版.
[86]阿吉.阿布里米提.玉素甫主编.维吾尔医学基础理论[M]：乌鲁木齐：卫生厅人民卫生出版社,1988.
[87]伊沙克江·马合穆德,主编.中国医学百科全书维吾尔医学分册[M].第一册.乌鲁木齐：新疆人民卫生出版社.1988.第一版.
[88]阿地里江·阿布力米提不同致病因素与异常黑胆质证候模型建立及其NEI网络和代谢组学的研究[D].新疆：新疆医科大学博士研究生论文,2010.
[89]哈木拉提.吾甫尔.维吾尔医气质、体液论及其现代研究[M].新疆科学技术出版社.2003；34-38.
[90]Morris RG, Garrud P, Rawlins, JN, et al. Place navigation impaired in rats with hippocampal lesions. Nature,1982,297(5868):681-683.
[91]Fischer W, Chen KS, Gage FH, et al. Progressive decline in spatial learning and integrity of forebrain cholinergic neurons in rats during aging[J]. Neurobiol Aging, 1992,13(1):9-23.
[92]AndreasK. Functional neuroimaging in Alzheimer's type dementia.J Neurol Sci,2002,203;247-251.
[93]万晓珊.老年性痴呆的病理特征与防治对策[J].医学与社会,2006,19(12)：13-14.
[94]Forloni G Chiesa R, Smiorldo S, et al. Apoptosis mediated neuro toxieity induced by chornic application of beat amyloid fragament 25-35[J].Neuroreport,1993, 4:523-526.
[95]Loo DT Copani A, pike CJ, et al. Apopotsis is induced by beta amyloid incultured central nevorus system neurons[J]. Proc Natl AcadSci. USA,1993,90:7951-7955.
[96]S Wolf gang, J M contreras, P istabelle, et al. Structure based 3DQSAR and design of novel acetylcholinesteras inhibitors [J]. Comput Aided Mol Des,2001,15:395-410.
[97]Tabaton M. Ultrastructural localization of β-amyloid tau and ubiduitin epitopes in extracellular neurofibrillary tangles[J]. Proe Natl Acad sci USA,1991, 88:2098-2102.
[98]Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease[J]. Brain Pathol.1996,6(4):493.
[99]李学坤,左萍萍. Alzlleimer病中p淀粉样蛋白的毒性作用[J].国外医学·生理.病理科学与临床分册,2001,21(5)：363-365.
[100]Abe E, Casmaenti F, Giovannelli L, et al. Administration of amyloid β-petides into the medical septum of rats decrease acetycholine release from hippocmapus in vivo[J]. Brain Res,1994,636:162-164.
[101]Parameshwaran K, Dhanasekaran M, Suppiramaniam V Amyloid betapeptides and glutaxnatergic synaptic dysregulation[J]. Neurol,2007,24.
[102]Li F, Calingasan NY, Yu F, et al Increased plaque burden in brain of APP mutant MnSOD heterozygous knockout mice[J]. Neurochem,2004,89(5):1308-1312.
[103]Xie, H. Litersky, J.M., Hartigan, J.A. et al. The interrelationship between selective Tau phosphorylation and micro tubule association[J]. Brain Res,1998, 798(1-2):173-183.
[104]王哗,顾振纶,秦正红.蛋白质错误折叠与神经退行性疾病[J].中国临床神经科学,2005,13(4)：422-426.
[105]李静,周东华,王延红.海马注射p-淀粉样蛋白建立阿尔茨海默病大鼠模型的实验研究[J].中国临床神经科学,2008；16(5)：467-470.
[106]SasakiT, Kitagawa K, Yamagata K, et al.Amelioration of hippocampal neuronal damage after transient forebrain is-chemia in cyclooxygenase-2-deficient mice[J].Cereb BloodFlowMetab,2004,24(1):107-113.
[107]Chang SH, Liu CH, Conway R, et al Role of prostagand in E2 denpendent angiogenic switch in cyelooxgenase-2 induced breast cancer progression[J]. PNAS, 2004,101(2):591-596
[108]Lin MT, Lee RC, Yang PC, et al Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanismin human lung adenocarcinoma CLI.0 Cells, Invovement of phoshutioly liositol3-kinuse/Aktlathway[J]. Bio Chem,2001,276(52):48997-49002.
[109]陈莉芬,陶陶,余震等.阿魏酸钠对缺血缺氧致脑血管内皮细胞IκB-α、NF-κB表达的影响[J].第二军医大学学报,2007,29(1)：228-230.
[110]Bours V, Bentires-AljM, HellinAC, et al. Nuelear factor-kappa B, cancer, and apoptosis[J]. Bioehem 2000,60(8):1085-1089.
[111]Michael JM, SankarG-Signal transduction throngh NF-KB[J].Immunoloday,1998, 19:80-88.
[112]App Ieby SB, Ristimaki A, Neilson K, et al. Strature of the human cyclo-oxygenas-2gene [J]. Biochem,1994,302(Pt3):723-727.
[113]张世仪.一氧化氮与Alzheimer病[J].中国神经免疫学和神经病学杂志,2005,12(1)：29-30.
[114]韦道祥,陈俊抛.小胶质细胞与阿尔茨海默病[J]·国外医学·老年医学分册,2000,11：248-250.
[115]苏丙.Ap致痴呆老龄大鼠模型海马MARCKS表达变化机制及中药调节作用研究[D]北京：北京中医药大学博士论文.2010.
[116]Simonian NA, Coyle JT. oxidative stress in neuro degenerative diseases[J]. Annu Rev pharmarol Toxieal,1996;36:83-106.
[117]Yan SD, chen X, Fu J, et al RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease[J]. Nature,1996:382(6593):685-91.
[118]Harris ME, Hensley K, Butterfiexd A, et al. Direct evidence of oxidative injury produced by the Alzheimer'sβ-amyloid PePtide(1-40)in cultured hippocampal neurons[J].ExP Neurol,1995;131:193
[119]Marcus D, Thomas C. Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease[J].Exp Neurol,1998:150(1):40-4.
[120]Hensley K, Hall N, subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of Protein oxidation[J]. Neuroehem,1995:65(5):2146-56.
[121]Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells fromvfamilial Alzheimer's Patients[J]. Free Rad. Bio Med.2002(33):1372-1379.
[122]Butterfield D. A, Jennifer D, Chava P, et al. Evidence of oxidative damage in Alzheimer's disease brain:central role for amyloid beta-peptide[J]. Trends Mol. Med,2001,7(12):548-554.
[123]Vina J, Loret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants:prevention of oxidative stress[J]. Mol Aspects Med,2004, 25:117-123.
[124]smith Perry G, Riekey P, et al. Oxidative damage in Alzheimer's[J]. Nature, 1996:382(6587):120-131.
[125]Polidori MC. Oxidative stress and risk factors for Altheimer's disease:clues to prevention and therapy[J]. Alzheimers Dis,2004;6(2):185-91.
[126]Migliorea L, Fontanaa 1, Colognatoa R, et al. searching for the role and the most sultable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases[J]. Neurobiology of Aging,2005;26:587-595.
[127]张益,叶燕,唐秦.阿托伐他汀对阿尔茨海默病患者血清SOD、MDA和OX-LDL的影响[J].重庆医学,2009,38(12)：1527-1528.
[128]裘晟 姜黄素改善小鼠学习记忆能力及神经保护作用的机制研究[D].暨南大学硕士学位论文,2007.
[129]Fassbender K, Masteers C, Beyreuther K. Alzheimer's disease:molecular concepts and therapeutic targets[J]. Neurology,2001,55(6):865-877.
[130]John ER. Psychobiology[M]. New York:Academic Press.1971,199-200.
[131]刘梅,杨胜利.乙酰胆碱及其受体的非神经递质作用和肿瘤肿瘤学[J].2006,01：105-108.
[132]Miyazawa A, Fujiyoshi Y, Unwinn. Structure and gating mechanism of the acetylcholine receptor pore[J]. Nature,2003,423:949-955.
[133]Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders[J]. Psyc hop har macol,2004, 18:457-474.
[134]徐江平,刘传绩.中枢烟碱受体与阿尔茨海默病[J].中国药理学通报,1995；11(1)：9-12.
[135]Nilsson L, Nordberg A, Hardy J, et al. Physostigmine restores 3H-acetylcholine from Alzheimer's brain sclices to normal level[J]. Neuro Trans,1986:67:275-279.
[136]Dekosky S. Upregulation of choline acetyltransefrase activity in hippocampus and frontal cortex of elderly subjects with mildcognitive impairment[J]. Ann Neurol, 2002,51(2):145-155.
[137]Caldeorn FH, Bernhard R, et al. Toxic effets of aceytlcholinesterase on neuronal and glial-like cells in vitor[J]. Mol Pyschiarry,1998,3(3):247-255.
[138]Nelson T J Alkon D L. Oxidation of cholesterol by amyloid precursor production and Fibril Formation to a Much Larger Extent than Necrotic-like Death in CGNs[J]. Alzheimer's Dis 2007,12(3):211-220.
[139]Berson A, Knobloch M, Hanan M, et al. Changes in readthough acetylcholinesterase expression modulate amyloid-beta Pathology[J]. Brain,2008,131(Ptl):109-119.
[140]Auld D S, Komeccook T J, Bastianetto S, et al. Alzheimer's' disease and the basal forebrain cholinergic system:relation to beta-amyloid peptides, cognition, and treatment strategies[J]. Prog Neurobiol,2002,68(3):209-245.
[141]Colom IV Diaz ME, Beers DR, et al. Role of potassium channels in amyloid-induched cell death [J]. Neuorchem,1998,70:1925-1934.
[142]Morris RGM, Development of a water maze procedure for studying;spetial learning in the rat [J].Neurosci Meth,1984, 11(1):47-60.
[143]袁德培.补肾活血化痰方对胆碱能损伤痴呆大鼠作用的分子机制研究.湖北中医学院博士研究生论文,2004.
[144]李文德,吴玉娥,阂凡贵.恒河猴大脑注射Aβ1-42和Thiorphan对胆碱能神经元影响的研究[J].基础医学,2009,23：7-10.
[145]牛丰南,孙宗正.阿尔茨海默病早期诊断的分子靶标研究进展(J).国际神病学神经外科学杂志,2009；36(1)：86-90.
[146]姚洁,王培昌.脑脊液生物学标志物的检测在阿尔茨海默病诊断中的应用(J)中国老年学杂志,2007；27(16)：1631-5.
[147]许国旺,路鑫,杨胜利.代谢组学研究进展[J].中国医学科学院学报,2007；29(6)：701-11.
[148]艾斯克尔·吐拉洪,哈木拉提·吾甫尔,巴吐尔·买买提明等.基于NMR的维吾尔医异常黑胆质型肿瘤患者血浆代谢组学分析[J].科技导报2009,27(13)27-29.
[149]王红强,马艳,马晓慧.新疆和田地区667例60岁以上老人长寿影响因素分析[J].热带医学杂志,2011,10：73-76.
[150]Alzheimer's Disease International World Alzheimer Report[R]. London, United Kingdom:King's College,2009.
[151Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease[J]. Alzheimers Dement 2008;4:65-79.
[152]Hong YK, Park SH, et al., Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease[J]. Ethnopharmacol.2011,134(3):1028-1032.
[153]Jeon S, Bose S, Hur J, et al. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease[J]. Ethnopharmacol.2011,137(1):783-9.
[154]徐月英.系统论原理在中医证研究中的运用[J].医学与哲学(人文社会医学版),2006,27(7)：65-66.
[155]李继明.证的主观性与客观性[J].成都中医药大学学报,2006,29(3).
[156]沈自尹.系统生物学和中医证的研究[J].中国中西医结合杂志,2005,25(3)：225-228.
[157]洪玉.新疆维汉两民族阿尔茨海默病的分子流行病学研究[D].乌鲁木齐：新疆医科大学博士论文.2008.
[158]哈木拉提·吾甫尔,阿不都热依木·玉素甫,努尔买买提·艾买提.异常黑胆质新论[M].新疆科学技术出版社,2010.
[159]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220.
[160]何彦丽,应逸,许艳丽等.杞多糖对荷瘤小鼠肿瘤微环境T淋巴细胞亚群及树突状细胞的影响[J].中西医结合学报,2005,3(5)：374-376.
[161]穆哈穆德.艾克拜尔,艾尔扎尼主编.米扎尼提普(波斯文)[M]：拉合尔伊斯兰出版社,1344年(农历)：85-92.
[162]斯依提.穆哈穆德.候赛音主编.麦合孜尼艾地维亚(草药宝库)(波斯文)[M]：印度吉维力可西瓦出版社.1988,251-292.
[163]姜波,严妍,吴娟芪归健脑颗粒对老年性痴呆大鼠学习记忆及脑组织nNOS、COX-2蛋白表达的影响[J].江苏大学学报(医学版)2009,05：21-24.
[164]Du Y, Wooten M C, and Wooten M W. Oxidative damage to the promoter region. of SQSTMl/p62 is common to neurodegenerative disease[J]. Neurobiol Dis,2009. 35(2):302-310.
[165]Bennett S, Grant M M, and Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease:a commonpathology[J]. Alzheimers Dis,2009.17(2):245-257.
[1]MichaelisML. Drugs targeting Alzheimers disease:some things old and some things new[J]. PharmacolExpTher,2003,304(3):897-904.
[2]庄莹,陈杰.阿尔茨海默病病因及发病机制研究进展[J].吉林医药学院学报,2008,29(4)：101-103.
[3]郭蕾,王永炎,张志斌.关于证候概念的诠释[J].北京中医药大学学报,2003,26(2)：5-8.
[4]赵慧辉,王伟.病证结合证候模型研究基本思路[J].中华中医药杂,2006,21(12)：762-764
[5]吴同玉,高碧珍.病证结合动物模型的模式探讨[J].中国中医药信息杂志,2009,12(16)：6-7.
[6]高冰冰,徐淑萍,刘新民,王立为.开心散与去茯苓开心散改善拟AD动物学习记忆作用比较[J].中国比较医学杂志,2010,7(20)：57-61.
[7]LambertMP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent cen-tral nervous system neurotoxins[J]. Proc NatlAcAD SciUSA,1998,95(11):6448-6453.
[8]Kayed R, HeAD E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies commonmechanism of pathogenesis[J]. Science,2003,300(5618): 486-489.
[9]代建峰,高建青,方三华.不同治法对老年性痴呆大鼠脑组织海马CA1区椎体细胞的影响[J].中国中医药科技,2009,7(16)：302-303.
[10]牛英才,周丽,张晓杰.加减地黄饮子对阿尔茨海默病大鼠模型的实验研究[J].陕西中医药,2007,5(28)：620-621.
[11]周龙岗,张志慧.通心络对β-淀粉样蛋白脑室注射所致阿尔茨海默病模型大鼠干预作用研究[J].络病学基础与临床研究,2006,(5)：52-53.
[12]张雪飞.氯化铝中毒小鼠不同脑区M受体含量的比较观察[J].青海医学院学报,2002,23(1)：10-12.
[13]焦俊英贾成文,等.醒脑增智方对AD鼠GSH-PX、SOD、MDA影响的实验研究[J].陕西中医,2006,27(6)497-498.
[14]张妍,林青,唐民科,等.复方丹参对老年痴呆模型大鼠海马和大脑皮层ChAT、 AchE活性的影响[J].北京中医药大学学报,2008,31(3)：192-195.
[15]张晓裕,何利明,侯军代,等.去痴灵对AD模型小鼠学习记忆及脑内突触体素表达的影响[J].中国老年学杂志,2010,30(4)：495-498.
[16]胡利,吴正治.疏肝解郁法对老年性痴呆模型神经细胞凋亡的机理研究[J].中医药导报,2010,16(7)：1-3.
[17]胡玉萍,袁德培.千层塔合剂对AD模型大鼠学习记忆能力及细胞凋亡的影响[J].辽宁中医杂志,2009,36(19)：1807-1810.
[18]吴同玉,高碧珍.病证结合动物模型的模式探讨[J].中国中医药信息杂志,2009,12(16)：6-7.
[19]陈向良,袁长津,袁梦石.损伤杏仁核制备阳虚阿尔茨海默病大鼠模型[J].中国老年学杂志,2007,27(1)：137-138.
[20]阎玥,王桐生,等.肝郁脾虚证模型大鼠HPA轴中枢相关受体的表达及疏肝健脾方药的干预作用[J].上海中医药杂志,2010,44(2)：58-60.
[21]王桐生,谢鸣.肝郁模型大鼠行为学与脑单胺递质的变化及柴胡的干预作用[J].中华中医药杂志,2008,10(23)：934-935.
[22]战丽彬,徐枫,董玉宽,等.滋补脾阴方药对老龄大鼠脑线粒体膜ATP酶活性的影响[J].中药药理与临床2000,16(1)24-25.
[23]李明陈,嫚茵,吴正治.补肝养髓方对老年性痴呆模型皮质神经元RNA和Nissl体的定量研究[J].深圳中西医结合杂志,2007,6(17)：136-137.
[24]游龙武,吴正治,李明.补肝养髓方对自发老年性痴呆模型神经信使分子一氧化氮代谢的影响[J].中国临床康复,2004,8(19)：3846-3847.
[25]刘志承,吴正治,李明.补肝养髓方对自发老年性痴呆模型中枢胆碱能系统活性的影响[J].中西医结合心脑血管病变,2004,7(2)：402-403.
[26]吴正治,张艳萍,王怀龄.补肝养髓方对自发老年性痴呆模型氧自由基损伤的定性定量研究[J].中国中医药科技,2007,11(7)：442-443.
[27]吴正治,李映红,李明.补肝养髓方对自发老年性痴呆模型突触可塑性的电镜定量研究.中国中医药科技,2007,11(6)：444-445.
[28]田金洲,杨承芝,盛彤,等.可疑痴呆人群中阿尔茨海默病临床前的认知损害及其与中医证候的关系[J].湖北中医学院学报,1999,11(4)：49-55.
[29]宋彩梅,王红梅.肾虚型老年痴呆动物模型的建立[J].现代中西医结合杂志,2011,22(8)：2744-2745.
[30]周乐全,丁胜元.阴虚对老年模型大鼠学习记忆的影响[J].广州中医药大学学报,2001,18(3)：57-59.
[31]陈京萍,周乐全.六味地黄汤对老年阴虚大鼠学习记忆能力的改善作用[J].中药新药与临床药理,2001,12(7)：282-283.
[32]黄兆胜,孙维广.养寿丹对阿尔茨海默病肾阳虚模型大鼠学习记忆的影响[J].中成药,2002,24(2)：113-114.
[33]刘明平,黄兆胜.养寿丹对Alzheimer病肾阳虚模型大鼠中枢胆碱能神经递质和细胞因子的影响[J].中国实验方剂学杂志,2003,9(10)：19-20.
[34]尚冰,李德新.脾气虚证、脾阴虚证、脾阳虚证模型大鼠MDA、SOD、GsH-Px、 T-AOC、8-OHdG、端粒长度变化的实验研究[D].辽宁中医药大学博士论文,2006.
[35]王彩霞林庶茹.Alzheimer型痴呆大白鼠病证结合模型的实验研究[J].辽宁中医杂志,1998,25(3)：141-142.
[36]王彩霞,李德新,等.理脾阴正方提高Alzheimer痴呆模型动物学习记忆能力的机理探讨[J].辽宁中医杂志,2002,29(4)：242-243.
[37]战丽彬,刘莉,宫晓洋,等.脾阴虚痴呆证病结合模型建立及滋补脾阴方药对其影响的实验研究[J].中华中医药学刊,2008,26(2)：9-12.
[38]战丽彬,宫晓洋,等.脾阴虚痴呆大鼠不同脑区Snk-SPAR路径及滋补脾阴方药调控作用研究[J].世界科学技术-中医药现代化.中医研究,2011,13(5)836-841.
[39]战丽彬,刘莉,等.滋补脾阴方药对脾阴虚痴呆大鼠海马蛋白质组学影响的研究[J].世界科学技术-中医药现代化.中医研究,2011,13(3)480-486.
[40]史宏,张静.茵陈五苓散提高痴呆小鼠脑组织抗氧化能力的实验研究[J].广西中医药,2009,1(32)：55-56.
[1]阿吉·阿布里米提,玉素甫,主编.维吾尔医学基础理论[M].乌鲁木齐：新疆人民卫生出版社,1988：114-144.
[2]南京中医药大学总编审.中华本草维吾尔医药卷[M]；上海科学技术出版社,2005,12(1)：101-176.
[3]阿依努尔·买提斯迪克,尼加提·热合曼,哈木拉提·吾甫尔.等异常黑胆质证候模型下丘脑-垂体-肾上腺轴组织形态学观察[J],新疆医科大学学报2005(28)10：907-908.
[4]阿依努尔·买提斯迪克,尼加提·热合曼,哈木拉提·吾甫尔.等异常黑胆质证候模型下丘脑-垂体-肾上腺轴组织形态学观察[J],新疆医科大学学报2005(28)10：908-909.
[5]努尔买买提.艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究[D].博士论文.2007.
[6]阿依努尔·买提斯迪克,胡汉华,哈木拉提·吾甫尔,等.异常黑胆质证候模型支配器官组织细胞超微结构观察[J].新疆医科大学学报2005(28)10：912-914.
[7]TanZ, NagataS. PVNc-fos expression, HPA xis response and immune cell distribution during restraistress. JUOEH,2002,24(2):1312149.
[8]BrattAM, KelleySP, KnowlesJP, et al. Longterm modulation of the HPA axis by the hippocampus. Behaioral, biochemical and immunological endpoints in rats exposed to chronic mild stress[J]. Psychoneuroendocrinolgy,2001,26(2):121-145.
[9]SimpkissJL, DevineDP. Responses of the HPA axis after chronic variable stress:effects of novel and famili stressors[J].NeuroEndocrinol,2003,24(122):97-103.
[10]哈木拉提·吾甫尔.维吾尔医气质、体液伦及其现代研究[M].乌鲁木齐：新疆科学技术出版社,2003.152-153.
[11]哈木拉提·吾甫尔,阿不都热依木·玉苏甫,吐尔逊·吾甫尔.维医异常体液分型与年龄、性别关系的探讨[J].中国民族民间医药杂志,2003,(61)：84-86.
[12]徐卫方,哈木拉提·吾甫尔等异常黑胆质与肾虚痰瘀的关系研究[J].新疆医科大学学报,2005,28(4)：300-304.
[13]阿不都热依木·玉素甫,李林,哈木拉提·吾甫尔等.维医异常体液分型及其与氧化-抗氧化系统关系的研究[J].中国中医基础医学杂志,2004,10(8)：61-62.
[14]努尔买买提·艾买提,哈木拉提·吾甫尔,阿依努尔·买提斯迪克.异常黑胆质载体动物模型免疫学本质的研究[J].中国中医基础医学杂志,2006,12(12)：903-905.
[15]阿依努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提·艾买提,等.异常黑胆质证载体动物模型的建立及其自然恢复反证[J].新疆医科大学学报,2006,29(10)：910-914.
[16]阿衣努尔·买提斯迪克,哈木拉提·吾甫尔,努尔买买提·艾买提,等.异常黑胆质载体动物饮食量和饮水量的观察[J].新疆中医药,2006,24(1)：5-7.
[17]哈木拉提·吾甫尔,阿依努尔·买提斯迪克,努尔买买提·艾买提等.维医异常黑胆质证载体动物模型的评价[J].中国中医基础医学杂志,2007,13(3)：186-188.
[18]尼加提·热合木,阿依努尔‘买提斯迪克,哈木拉提·吾甫尔等.异常黑胆质载体动物模型支配器官的组织形态学改变[J].新疆医科大学学报,2006,29(10)：917-918.
[19]阿依努尔·买提斯迪克,胡汉华,哈木拉提·吾甫尔等.异常黑胆质载体动物模型支配器官组织细胞超微结构观察[J].新疆医科大学学报,2006,29(10)：919-921.
[20]Jacob Raber, Susan F. Akana, Seema Bhatnagar, et al. Hypothalamic-Pituitary-Adrenal Dysfunction in Apoe-/-Mice:Possible Role in Behavioral and Metabolic AlterationsThe Journal of Neuroscience, March 1,2000,20(5):2064-2071.
[21]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提等.维吾尔族异常黑胆质型患者基因多态性研究[J].中华医学遗传学杂志,2003,20(1)：77-78.
[22]哈木拉提·吾甫尔.维吾尔医学气质、体液论及其现代研究[M].新疆科技术出版社,2003,7：75-77.
[23]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提等.ApoE基因多态型与维吾尔族高血压患者的关系[J].中国免疫学杂志2003,Vol.19：108-110.
[24]哈木拉提·吾甫尔,艾斯卡尔‘依米提,伊力哈木江‘沙比提,等.ApoE基因多态性与异常黑胆质型疾病的关系[J].中华医学遗传学杂志,2003,20(6)：549-550.
[25]努尔买买提.艾买提.异常黑胆质证候模型及其神经-内分泌-免疫网络紊乱的研究.乌鲁木齐：新疆医科大学博士论文.2007.
[26]D. A. Dubrovin.异常黑胆质型ApoE-ko动物的模型建立.维吾尔医药及其他传统医学研究与应用[C].新疆乌鲁木齐.2003.6.乌鲁木齐.新疆人民卫生出版社.2007：10-13.
[27]沙吉旦·阿不都热衣木,金伟,热娜古丽等.复杂性疾病血栓前状态指标变化的共性研究[J].科技导报,2007,24(20)：66-69.
[28]张莉,哈木拉提·吾甫尔,胡尔西旦等.异常黑胆质载体动物肿瘤模型的建立及其神经内分泌免疫指标的改变[J].国际病理科学与临床杂志2007(5)：963-966.
[29]张莉,哈木拉提·吾甫尔,玛依努尔等.恶性肿瘤的维医分型及其神经内分泌免疫网络紊乱研究[J].中国中医基础医学杂志2008,24(2)：220-223.
[30]哈木拉提·吾甫尔,李风森,杨剑等.西医重度哮喘、中医虚哮型哮喘和维医异常黑胆质哮喘的交互性研究[J].科技导报,2008,8(6)：45-49.
[31]Sajida Abdureyim, Nurmuhammat Amat, Anwar Umar, et al. Anti-inflammatory, immuno-modulatory and heme oxygenase-1 inhibitory activities of Ravan Napas, a formulation of Uighur Traditional Medicine, in a rat model of allergic asthma[J]. Evidence-based Complementary and Alternative Medicine,2010.221-223.
[32]克丽别娜·吐尔逊,伊力哈木·沙比提,王雯等.维医异常黑胆质性哮喘β_2AR基因多态性研究[J].新疆医科大学学报,2007,(09)：88-90.
[33]艾尼瓦尔·卡德尔,哈木拉提,庞辉群.新疆维族夜间哮喘发作期患者维吾尔医辨证分型特点分析[J].中国民族医药杂志,2000,6(4)：29-30.
[34]Fleur M, Howells, Vinienne A, Rusell. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease[J]. Behavioral Brain Research,2005, 165(2):210-220
[35]邓云华,陈映玲,陈兴平等.介菌多糖核酸、胸腺肽影响正常和免疫抑制[J].中华医学实践杂志,2003,2(1)：21.
[36]阿布都热依木.玉苏甫.异常黑胆质成熟剂对HepG2细胞及其相关基因表达的影响.乌鲁木齐：新疆医科大学博士论文,2005.
[37]努尔买买提,哈木拉提·吾甫尔.异常黑胆质成熟剂和清除剂对小鼠神经内分泌免疫网络的调节作用.维吾尔医学及其他传统医学的研究与应用[C].乌鲁木齐：新疆人民卫生出版社2003：11-12.
[38]邹浩军,明亮.黄酮类化合物抗炎免疫及抗衰老药理研究进展[J].安徽卫生职业技术学院学报2003,3(6)48-50.
[39]Abdiryim Yusup, Halmurat Upur, Xirali. The effect of Abnormal Savda Munziq total flavonoids on the proliferation, apoptosis and correlative gene expression in human hepatoma(HepG2)cells[J]. Toxicology Letters,2006.164S-S250
[40]Abdiryim Yusup, Halmurat Upur. Protective effects of Abnormal Savda Mushil to mitochondrial oxidative damage[J]. Free Radical Biology and Medicine, 2002;33(1):s240-s240.
[41]Abdiryim· yusup, Halmurat·upur. Isabelle Baudrimont Cytotoxicity of abnormal savda munziq inhibition of cell growth and DAN, protein synthesis in HEPG2 cells[J]. Toxicology and applied pharmacology,2004.690-692.
[42]许士凯,王晓东,赵军宁等天然药物抗衰老有效成分研究进展(之三)[J].现代中西医结合杂志2005,14(21),2773-2775.
[43]魏巍.中药甙类活性成分抗辐射作用的研究[J].中国辐射卫生2006,15(2)251-252.
[44]刘颖,金宏,程义勇.多糖生物活性及其作用机制研究进展[J].中国公共卫生2006,22(5)627-629.
[45]林旭凯,陈文玲,李盛鹏,等.复方活性多糖对实验大鼠免疫调节作用研究[J].现代预防医学,2004,31(4)：509-510.
[46]穆哈穆德·艾克拜尔,艾尔扎尼主编.米扎尼提普(波斯文)[M]：拉合尔伊斯兰出版社,1344年(农历)：85-92.
[47]哈木拉提·吾甫尔,努尔买买提·艾买提.异常黑胆质载体动物模型的下丘脑-垂体-肾上腺轴功能紊乱的物质基础研究[J].中国中医基础医学杂志,2007(13)9：125-128
[48]努尔买买提·艾买提,哈木拉提·吾甫尔,阿迪力等.异常黑胆质成熟剂对异常黑胆质载体动物模型下丘脑-垂体-肾上腺轴的调节作用研究[J].时珍国医国药,2007(11)：69-71.
[49]阿地力江·阿不力米提.哈木拉提·吾甫尔.胡汉华等.异常黑胆质成熟剂对异常黑胆质载体动物模型支配器官细胞超微结构的影响[J].中国中医基础医学杂志,2008 14(1)：129-131.
[50]Halmurat Upur, Anwar Umar, Adil Ablimit, et al. Effect of Abnormal Savda Munziq on morphological and ultrastructural changes of target organs in an Abnormal Savda syndronme animal model[J]. Fundam Clin Pharmacol,2007,21(l):69-69.
[51]Halmurat Upur, Anwar Umar, Adil Ablimit, et al. The effect of Abnormal Savda Munziq on morphological and ultrastructural changes of hypothalamus[J]. Fundam Clin Pharmacol,2007,21(1):74-74.
[52]Nurmuhammat Amat, Halmurat Upur, Adiljan Ablimit, et al. Immunomodulatory combined stress mice[J]. Journal of Ethnopharmacology,2009,122(1):42-47.
[53]Batur mamtimin, Halmurat upur, Fu-hua, Aynur matsidik and Rena Rahim. Plasma magnetic resonance vevealing the relationship of different tumor and the disease homology theory of traditional Uyghur medicine. Chinese journal of integrative Medicine,2011(17)2:111-115.
[54]Peiyuan Yin, Patamu Mohemaiti, Jing Chen, et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry[J]. Journal of Chromatography B,2008, Vol 871, (2):322-327.
[55]阿布都艾尼,阿不都热依木·玉苏甫,哈木拉提等.异常黑胆质成熟剂和清除剂对OH.引发的DNA损伤的保护作用[J].中药药理与临床,2000；16(3)：34-36.
[56]Abdiryim Yusup, Halmurat U, Umar A, et al. Protective effects of Munziq and Mushil of Abnormal Savda to mitochondrial oxidative damage[J]. Fundam Clin Pharmacol 2004;18(4):471-6.
[57]哈木拉提,阿不都热依木,阿布都艾尼等.维吾尔医成熟剂和清除剂抗活性氧的作用研究[J].中国民族医药杂志,2000,6(3)：30-32.
[58]沙吉旦·阿不都热衣木,金伟,热娜古丽·艾则孜等.复杂性疾病血栓前状态指标变化的共性研究[J].科技导报,2007,12(200)：120-123.
[59]艾斯卡尔·伊米提,哈木拉提·吾甫尔,布再娜甫·伊力哈木.维吾尔医成熟剂和清除剂诱导T淋巴瘤细胞凋亡的研究[J].中国药理与临床,2000,16(2)：33-34.
[60]哈木拉提·吾甫尔,艾斯卡尔·依米提,伊力哈木江·沙比提.异常黑胆质成熟剂与清除剂对人Hela细胞凋亡基因表达的影响[J].细胞与分子免疫学杂志,2001,17(2)：109-111.
[61]Abdiryim Yusup, Halmurat U, Umar A, et al. Protective effects of Munziq and Mushil of Abnormal Savda to mitochondrial oxidative damage[J]. Fundam Clin Pharmacol,2004,18(4):471-6
[62]Nurmuhammat Amat, Halmurat Upur, Biljana Blazekovi'c. In vivo hepatoprotective activity of the aqueous extract of Artemisia absinthium L. against chemically and immunologically induced liver injuries in mice[J]. Journal of Ethnopharmacology, 2010,131,478-484
[63]Halmurat Upur, Nurmuhammat Amat. Protective effect of Cichorium glandulosum root extract on carbon tetrachloride-induced and galactosamine-induced hepatotoxicity in mice[J]. Food and chemical toxicology,2009.123-126
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |